<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="3.0" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">plos</journal-id>
<journal-id journal-id-type="nlm-ta">PLoS Comput Biol</journal-id>
<journal-id journal-id-type="pmc">ploscomp</journal-id><journal-title-group>
<journal-title>PLoS Computational Biology</journal-title></journal-title-group>
<issn pub-type="ppub">1553-734X</issn>
<issn pub-type="epub">1553-7358</issn>
<publisher>
<publisher-name>Public Library of Science</publisher-name>
<publisher-loc>San Francisco, USA</publisher-loc></publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">PCOMPBIOL-D-13-01555</article-id>
<article-id pub-id-type="doi">10.1371/journal.pcbi.1003509</article-id>
<article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Biology</subject><subj-group><subject>Anatomy and physiology</subject><subj-group><subject>Cardiovascular system</subject></subj-group></subj-group><subj-group><subject>Computational biology</subject><subj-group><subject>Biophysic al simulations</subject><subject>Systems biology</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine</subject><subj-group><subject>Cardiovascular</subject><subj-group><subject>Atherosclerosis</subject></subj-group></subj-group><subj-group><subject>Clinical research design</subject><subj-group><subject>Modeling</subject></subj-group></subj-group></subj-group></article-categories>
<title-group>
<article-title>An <italic>In-Silico</italic> Model of Lipoprotein Metabolism and Kinetics for the Evaluation of Targets and Biomarkers in the Reverse Cholesterol Transport Pathway</article-title>
<alt-title alt-title-type="running-head">A Model of Lipoprotein Metabolism and Kinetics</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Lu</surname><given-names>James</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Hübner</surname><given-names>Katrin</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Nanjee</surname><given-names>M. Nazeem</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Brinton</surname><given-names>Eliot A.</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Mazer</surname><given-names>Norman A.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib>
</contrib-group>
<aff id="aff1"><label>1</label><addr-line>F. Hoffmann-La Roche AG, pRED, Pharma Research &amp; Early Development, Clinical Pharmacology, Basel, Switzerland</addr-line></aff>
<aff id="aff2"><label>2</label><addr-line>BioQuant, University of Heidelberg, Heidelberg, Germany</addr-line></aff>
<aff id="aff3"><label>3</label><addr-line>Division of Cardiovascular Genetics, University of Utah, Salt Lake City, Utah, United States of America</addr-line></aff>
<aff id="aff4"><label>4</label><addr-line>Utah Foundation for Biomedical Research, Salt Lake City, Utah, United States of America</addr-line></aff>
<contrib-group>
<contrib contrib-type="editor" xlink:type="simple"><name name-style="western"><surname>Beard</surname><given-names>Daniel A.</given-names></name>
<role>Editor</role>
<xref ref-type="aff" rid="edit1"/></contrib>
</contrib-group>
<aff id="edit1"><addr-line>University of Michigan, United States of America</addr-line></aff>
<author-notes>
<corresp id="cor1">* E-mail: <email xlink:type="simple">james.lu.jl1@roche.com</email></corresp>
<fn fn-type="conflict"><p>I have read the journal's policy and have the following conflicts: JL and NAM are employees of F. Hoffmann-La Roche; JL and NAM have stock ownership of F. Hoffmann-La Roche. KH, MNN and EAB declare no competing interest.</p></fn>
<fn fn-type="con"><p>Analyzed the data: JL NAM. Contributed reagents/materials/analysis tools: JL NAM. Wrote the paper: JL KH MNN EAB NAM.</p></fn>
</author-notes>
<pub-date pub-type="collection"><month>3</month><year>2014</year></pub-date>
<pub-date pub-type="epub"><day>13</day><month>3</month><year>2014</year></pub-date>
<volume>10</volume>
<issue>3</issue>
<elocation-id>e1003509</elocation-id>
<history>
<date date-type="received"><day>2</day><month>9</month><year>2013</year></date>
<date date-type="accepted"><day>22</day><month>1</month><year>2014</year></date>
</history>
<permissions>
<copyright-year>2014</copyright-year>
<copyright-holder>Lu et al</copyright-holder><license xlink:type="simple"><license-p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions>
<abstract>
<p>High-density lipoprotein (HDL) is believed to play an important role in lowering cardiovascular disease (CVD) risk by mediating the process of reverse cholesterol transport (RCT). Via RCT, excess cholesterol from peripheral tissues is carried back to the liver and hence should lead to the reduction of atherosclerotic plaques. The recent failures of HDL-cholesterol (HDL-C) raising therapies have initiated a re-examination of the link between CVD risk and the rate of RCT, and have brought into question whether all target modulations that raise HDL-C would be atheroprotective. To help address these issues, a novel <italic>in-silico</italic> model has been built to incorporate modern concepts of HDL biology, including: the geometric structure of HDL linking the core radius with the number of ApoA-I molecules on it, and the regeneration of lipid-poor ApoA-I from spherical HDL due to remodeling processes. The ODE model has been calibrated using data from the literature and validated by simulating additional experiments not used in the calibration. Using a virtual population, we show that the model provides possible explanations for a number of well-known relationships in cholesterol metabolism, including the epidemiological relationship between HDL-C and CVD risk and the correlations between some HDL-related lipoprotein markers. In particular, the model has been used to explore two HDL-C raising target modulations, Cholesteryl Ester Transfer Protein (CETP) inhibition and ATP-binding cassette transporter member 1 (ABCA1) up-regulation. It predicts that while CETP inhibition would not result in an increased RCT rate, ABCA1 up-regulation should increase both HDL-C and RCT rate. Furthermore, the model predicts the two target modulations result in distinct changes in the lipoprotein measures. Finally, the model also allows for an evaluation of two candidate biomarkers for <italic>in-vivo</italic> whole-body ABCA1 activity: the absolute concentration and the % lipid-poor ApoA-I. These findings illustrate the potential utility of the model in drug development.</p>
</abstract>
<abstract abstract-type="summary"><title>Author Summary</title>
<p>Epidemiological studies have shown a strong inverse association between HDL-C and cardiovascular risk and led to the formulation of the “HDL cholesterol hypothesis”: under this hypothesis, interventions raising HDL-C should decrease risk. However, the recent failures of HDL-C raising therapies in improving cardiovascular disease risk in outcomes trials have suggested a need to revise the hypothesis to account for the contrary data. An “HDL flux hypothesis” has emerged: it is not HDL-C level <italic>per se</italic> which forms the basis for reducing risk, but it is the flux rate of reverse cholesterol transport that drives risk reduction. We propose that, the concentration of HDL cholesteryl ester in plasma simply reflects the ratio of input rate of reverse cholesterol transport into the HDL compartments to its clearance rate. A challenge in identifying targets under the new conceptual framework is the feedback process that occurs between the input rate and the clearance rate of HDL-C. To meet this challenge, we have built a systems model which incorporates the main processes of HDL metabolism to elucidate the relationships between target modulations and the reverse cholesterol transport rate.</p>
</abstract>
<funding-group><funding-statement>This work was supported by the Roche Postdoctoral Fellowship fund of F. Hoffmann-La Roche AG, Basel, Switzerland, project number RPF-153. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><page-count count="26"/></counts></article-meta>
</front>
<body><sec id="s1">
<title>Introduction</title>
<p>Epidemiological studies have shown that high levels of low-density lipoprotein cholesterol (LDL-C) as well as low levels of high-density lipoprotein cholesterol (HDL-C) are associated with increased cardiovascular disease (CVD) risk <xref ref-type="bibr" rid="pcbi.1003509-DiAngelantonio1">[1]</xref>, <xref ref-type="bibr" rid="pcbi.1003509-Larach1">[2]</xref>. While LDL-C lowering therapies have been shown consistently to reduce CVD risk, there is significant residual risk that remains to be managed <xref ref-type="bibr" rid="pcbi.1003509-Larach1">[2]</xref>. The strong inverse association between HDL-C and CVD risk has led to the “HDL-C hypothesis”, whereby all HDL-C raising therapies should be anti-atherogenic <xref ref-type="bibr" rid="pcbi.1003509-Larach1">[2]</xref>, <xref ref-type="bibr" rid="pcbi.1003509-Hersberger1">[3]</xref>. Currently, the anti-atherogenic activity of HDL is mainly attributed to its role in mediating reverse cholesterol transport (RCT), whereby cholesterol is effluxed from peripheral tissues and transported to the liver for biliary excretion <xref ref-type="bibr" rid="pcbi.1003509-Rothblat1">[4]</xref>. However, the recent failures of a number of HDL-C raising intervention trials <xref ref-type="bibr" rid="pcbi.1003509-Barter1">[5]</xref>–<xref ref-type="bibr" rid="pcbi.1003509-Schwartz1">[7]</xref> have called for a re-examination of the HDL-C hypothesis. It has long been thought that HDL-C is a reliable biomarker for cholesterol efflux from tissues <xref ref-type="bibr" rid="pcbi.1003509-Rosenson1">[8]</xref>. However, the several recent failed HDL-C raising intervention trials provide mounting evidence that at least under certain conditions, the plasma concentration of HDL-C, a very simple and static measure, is inadequate for characterizing the rate of RCT, which is a complex and dynamic process <xref ref-type="bibr" rid="pcbi.1003509-Rosenson1">[8]</xref>. A revision of the HDL-C hypothesis to the “HDL flux hypothesis” has been proposed, whereby interventions should be aimed at promoting cholesterol efflux to HDL, and hence the overall RCT rate, independently of their effects on HDL-C levels <xref ref-type="bibr" rid="pcbi.1003509-Rader1">[9]</xref>, <xref ref-type="bibr" rid="pcbi.1003509-Heinecke1">[10]</xref>. Hence, there is now a pressing need to better understand the role of HDL-C raising targets in the context of RCT and to identify biomarkers which could provide information on the flux rate through the RCT pathway <xref ref-type="bibr" rid="pcbi.1003509-Rosenson1">[8]</xref>. Our modeling effort is focused on addressing these issues.</p>
<p>A number of previous mathematical models have focused on various aspects of lipid metabolism; see <xref ref-type="bibr" rid="pcbi.1003509-deGraaf1">[11]</xref>, <xref ref-type="bibr" rid="pcbi.1003509-Lu1">[12]</xref> for recent reviews. Of the existing models, some describe metabolic processes at a mechanistic level <xref ref-type="bibr" rid="pcbi.1003509-Potter1">[13]</xref>–<xref ref-type="bibr" rid="pcbi.1003509-Tiemann1">[19]</xref>, while others have been empirically derived from tracer kinetic studies <xref ref-type="bibr" rid="pcbi.1003509-Ouguerram1">[20]</xref>–<xref ref-type="bibr" rid="pcbi.1003509-Chetiveaux1">[22]</xref>. In general these models were built to describe the dynamics of HDL and the other major lipoprotein classes, which include LDL, intermediate density lipoprotein (IDL) and very low density lipoprotein (VLDL), describing lipid transport between these particles mediated by the cholesteryl ester transport protein (CETP) in the normal or basal state, and the effects of genetic mutations and/or drug interventions on these processes. While valuable insights have been gained from these models, none can be used to predict the associated changes in the RCT rate since they lack a mechanistic description of ApoA-I dynamics and other key processes involved in the RCT pathway. The latter include the lipidation of lipid-poor ApoA-I via its interaction with ATP-binding cassette transporter member 1 (ABCA1), the key process in the initiation of RCT <xref ref-type="bibr" rid="pcbi.1003509-Rosenson1">[8]</xref>, as well as processes of HDL remodeling which lead to the delivery of cholesterol from HDL to other lipoproteins and cells, and the regeneration of lipid poor ApoA-I <xref ref-type="bibr" rid="pcbi.1003509-Rye1">[23]</xref>. In all the existing models except the ones by Hübner <italic>et al</italic> <xref ref-type="bibr" rid="pcbi.1003509-Hbner1">[16]</xref> and Adiels <italic>et al</italic> <xref ref-type="bibr" rid="pcbi.1003509-Adiels1">[24]</xref>, the dynamics of apolipoproteins that cover the surface of lipoprotein particles are not described. While each VLDL, IDL and LDL particle contains only one ApoB molecule per particle, for HDL particles the number of ApoA-I molecules per particle may vary from 2 to 4 or more depending on HDL size <xref ref-type="bibr" rid="pcbi.1003509-Mazer1">[25]</xref>. This variation results from HDL remodeling processes such as particle fusion, CETP-mediated lipid transport, lipolysis and esterification whereby particles can gain or lose core lipid content as well as ApoA-I molecules <xref ref-type="bibr" rid="pcbi.1003509-Rye1">[23]</xref>. While it has been shown experimentally and theoretically that the number of ApoA-I molecules on a given HDL particle is intrinsically linked to the particle size <xref ref-type="bibr" rid="pcbi.1003509-Mazer1">[25]</xref>, this important relationship has yet to be incorporated into a mechanistic model of HDL metabolism.</p>
<p>In this paper, we propose a novel model of lipoprotein metabolism and kinetics (the LMK model) that provides an integrated description of the dynamics of cholesterol and ApoA-I in plasma. In particular, the model captures the initiation of RCT from the lipidation of lipid-poor ApoA-I by the ABCA1 transporter, the generation of nascent discoidal and nascent spherical particles, HDL particle fusion, CETP mediated lipid transfer between HDL and other lipoproteins, and the dissociation of excess ApoA-I from mature spherical <italic>α</italic>-HDL due to remodeling processes. The model is calibrated to: lipoprotein measures for normal and CETP deficient subjects; cholesteryl ester (CE) and ApoA-I fluxes measured in normal subjects; data on the fractional catabolic rate (FCR) of ApoA-I. The structure and the kinetic constants of our model provide an explanation for the relationship between FCR of ApoA-I and HDL particle size. To our knowledge the LMK model is the first to provide a mechanistic basis for the linkage between the metabolism of ApoA-I and the cholesterol component of HDL. The model has been validated by simulating patients with genetic mutations in the HDL metabolism pathway and the predictions are compared with lipoprotein measures reported in literature. Finally, the model was used to evaluate targets that could potentially increase RCT and to identify relevant biomarkers, as part of the effort to support drug discovery and development using a model-based approach.</p>
</sec><sec id="s2">
<title>Results/Discussion</title>
<sec id="s2a">
<title>Model structure</title>
<p>The LMK model is shown schematically in <xref ref-type="fig" rid="pcbi-1003509-g001">Figure 1</xref>, focused on the RCT pathway and a number of targets contained within it, for instance CETP, ABCA1, ApoA-I and SRB1. The LMK model describes the synthesis of ApoA-I and the initiation of RCT by the interaction of lipid-poor ApoA-I with ABCA1 leading to the formation of mature, spherical <italic>α</italic>-HDL. The HDL remodeling processes represented in the model include: the fusion of spherical HDL particles (arrow 5 of <xref ref-type="fig" rid="pcbi-1003509-g001">Figure 1</xref>); the exchange and elimination of CE in spherical HDL by interaction with CETP (arrows 12–14) and SRB1 (arrow 7); the regeneration of lipid-poor ApoA-I from spherical HDL particles (arrow 3). Lipid-poor ApoA-I is assumed to be eliminated via the kidney (arrow 4), while the spherical HDL particles are assumed to be eliminated by a holo-uptake mechanism with a rate dependent on the particle size (arrow 6). The transfer and elimination of CE in LDL and VLDL pools are also represented (arrows 9–11). Our approach is to adequately describe the metabolic processes, while keeping the model as simple as possible. The representations of lipoprotein components and metabolic processes in the LMK model reflect these principles.</p>
<fig id="pcbi-1003509-g001" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1003509.g001</object-id><label>Figure 1</label><caption>
<title>A schematic representation of the model.</title>
<p>The arrows shown in the diagram denote the processes represented by the model and the boxes with italicized text denote mediators that are explicitly represented. The process arrows are numbered, refering to the reaction number shown in <xref ref-type="table" rid="pcbi-1003509-t002">Table 2</xref>. The arrows leading from the nascent sphere towards the <italic>α</italic>-HDL pool represent the 2 scenarios that may occur in the transformation of newly formed particles: they may either enter the <italic>α</italic>-HDL pool as distinct particles (the dashed arrow) or fuse with the existing ones (solid arrow).</p>
</caption><graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1003509.g001" position="float" xlink:type="simple"/></fig><sec id="s2a1">
<title>Lipoprotein representation</title>
<p>While HDL particles are heterogeneous in size and composition <xref ref-type="bibr" rid="pcbi.1003509-Rosenson1">[8]</xref>, for the purposes of understanding RCT we only consider two HDL particle classes: spherical, <italic>α</italic>-HDL and small, lipid-poor ApoA-I. Amongst the apolipoproteins and lipid species contained in <italic>α</italic>-HDL particles, the LMK model has an explicit representation of ApoA-I and CE. Although there are a large number of species in the HDL proteome (e.g., ApoA-II, ApoE) and lipidome (e.g., triglycerides, phospholipids) which may be relevant in particular diseased states, they play a secondary role in the characterization of RCT. We make the assumption that the protein moiety contains 60% ApoA-I by weight, with all other proteins contributing the remaining 40%. This is within the range of values reported in literature <xref ref-type="bibr" rid="pcbi.1003509-Mazer1">[25]</xref>, <xref ref-type="bibr" rid="pcbi.1003509-Scanu1">[26]</xref>. Under this assumption, the total concentration of ApoA-I is represented as an explicit variable that changes as a direct result of the metabolic processes described in the model while ApoA-II and other HDL apolipoproteins are implicit quantities: namely, they are assumed to change in concert with ApoA-I so as to keep the weight fraction constant. Similarly, the LMK model explicitly represents CE in the particle classes of <italic>α</italic>-HDL, VLDL and LDL but represents TG in <italic>α</italic>-HDL only implicitly. That is, the ratio of TG/CE in <italic>α</italic>-HDL particles is assumed to be 13% which is consistent with the range of values reported in healthy subjects <xref ref-type="bibr" rid="pcbi.1003509-Mazer1">[25]</xref>, <xref ref-type="bibr" rid="pcbi.1003509-Kontush1">[27]</xref>. The amounts of free cholesterol (FC) and phospholipids (PL) per HDL particle are implicitly represented in the LMK model: they depend on the <italic>α</italic>-HDL size, in a manner analogous to the treatment of PL in <xref ref-type="bibr" rid="pcbi.1003509-Hbner1">[16]</xref>. In particular, given the CE content of an <italic>α</italic>-HDL particle its core size can be inferred and the FC and PL content on the surface can be computed using the updated Shen model; see <xref ref-type="bibr" rid="pcbi.1003509-Mazer1">[25]</xref>. With our choice of lipoprotein representation, the species represented in the model are given in <xref ref-type="table" rid="pcbi-1003509-t001">Table 1</xref>.</p>
<table-wrap id="pcbi-1003509-t001" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1003509.t001</object-id><label>Table 1</label><caption>
<title>Species represented in the model.</title>
</caption><alternatives><graphic id="pcbi-1003509-t001-1" position="float" mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1003509.t001" xlink:type="simple"/>
<table><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup>
<thead>
<tr>
<td align="left" rowspan="1" colspan="1">Symbol</td>
<td align="left" rowspan="1" colspan="1">Description</td>
<td align="left" rowspan="1" colspan="1">Units</td>
</tr>
</thead>
<tbody>
<tr>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e001" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1">Lipid-poor ApoA-I</td>
<td align="left" rowspan="1" colspan="1">mg/dL</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e002" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1">ApoA-I in the <italic>α</italic>-HDL pool</td>
<td align="left" rowspan="1" colspan="1">mg/dL</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e003" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1">Particle concentration of <italic>α</italic>-HDL</td>
<td align="left" rowspan="1" colspan="1">mmol/dL</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e004" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1">cholesteryl ester in <italic>α</italic>-HDL</td>
<td align="left" rowspan="1" colspan="1">mg/dL</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e005" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1">cholesteryl ester in LDL</td>
<td align="left" rowspan="1" colspan="1">mg/dL</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e006" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1">cholesteryl ester in VLDL</td>
<td align="left" rowspan="1" colspan="1">mg/dL</td>
</tr>
</tbody>
</table>
</alternatives></table-wrap></sec><sec id="s2a2">
<title>Metabolic processes</title>
<p>The full list of reactions represented in the LMK model (as schematized in <xref ref-type="fig" rid="pcbi-1003509-g001">Figure 1</xref>) is shown in <xref ref-type="table" rid="pcbi-1003509-t002">Table 2</xref>. We would like to point out that the remodeling flux (arrow 3 of <xref ref-type="fig" rid="pcbi-1003509-g001">Figure 1</xref>) based on geometric concepts developed in <xref ref-type="bibr" rid="pcbi.1003509-Mazer1">[25]</xref> is an original contribution of our work. The remodeling flux expression, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e007" xlink:type="simple"/></inline-formula>, represents the excess ApoA-I within the pool of <italic>α</italic>-HDL particles given the core cholesteryl ester content, particle concentration and the amount of ApoA-I covering the surface. Its derivation based on geometric concepts of <italic>α</italic>-HDL particles is discussed in more detail in the <xref ref-type="sec" rid="s3">Methods</xref> section. The holo-uptake of <italic>α</italic>-HDL particles is thought to be mediated by a number of receptors, which are not well understood <xref ref-type="bibr" rid="pcbi.1003509-Moestrup1">[28]</xref>, <xref ref-type="bibr" rid="pcbi.1003509-Martinez1">[29]</xref>. In order to account for the possible size-dependence in the uptake rate of <italic>α</italic>-HDL particles, the functional dependence <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e008" xlink:type="simple"/></inline-formula> is utilized. This is also discussed in more detail in the <xref ref-type="sec" rid="s3">Methods</xref> section.</p>
<table-wrap id="pcbi-1003509-t002" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1003509.t002</object-id><label>Table 2</label><caption>
<title>Reactions represented in the model.</title>
</caption><alternatives><graphic id="pcbi-1003509-t002-2" position="float" mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1003509.t002" xlink:type="simple"/>
<table><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup>
<thead>
<tr>
<td align="left" rowspan="1" colspan="1">#</td>
<td align="left" rowspan="1" colspan="1">Reaction</td>
<td align="left" rowspan="1" colspan="1">Description</td>
<td align="left" rowspan="1" colspan="1">Rate expression</td>
<td align="left" rowspan="1" colspan="1">Ref.</td>
</tr>
</thead>
<tbody>
<tr>
<td align="left" rowspan="1" colspan="1">1</td>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e009" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1">ApoA-I synthesis</td>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e010" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1"><xref ref-type="bibr" rid="pcbi.1003509-Chetiveaux1">[22]</xref>, <xref ref-type="bibr" rid="pcbi.1003509-VelezCarrasco1">[88]</xref></td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">2</td>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e011" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1">Initiation of RCT by interaction with ABCA1</td>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e012" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1"><xref ref-type="bibr" rid="pcbi.1003509-Castro1">[79]</xref>, <xref ref-type="bibr" rid="pcbi.1003509-SorciThomas1">[80]</xref>, <xref ref-type="bibr" rid="pcbi.1003509-Schaefer3">[89]</xref></td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">3</td>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e013" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1">Regeneration of lipid-poor ApoA-I via HDL remodeling</td>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e014" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1"><xref ref-type="bibr" rid="pcbi.1003509-Chetiveaux1">[22]</xref>, <xref ref-type="bibr" rid="pcbi.1003509-Mazer1">[25]</xref>, <xref ref-type="bibr" rid="pcbi.1003509-Cavigiolio1">[76]</xref>, <xref ref-type="bibr" rid="pcbi.1003509-Barter2">[90]</xref>–<xref ref-type="bibr" rid="pcbi.1003509-Liang1">[92]</xref></td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">4</td>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e015" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1">Kidney removal of lipid-poor ApoA-I</td>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e016" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1"><xref ref-type="bibr" rid="pcbi.1003509-Brinton1">[43]</xref>, <xref ref-type="bibr" rid="pcbi.1003509-Ikewaki3">[48]</xref></td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">5</td>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e017" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1">Fusion of nascent spherical particles with mature <italic>α</italic>-HDL</td>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e018" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1"><xref ref-type="bibr" rid="pcbi.1003509-Rye1">[23]</xref>, <xref ref-type="bibr" rid="pcbi.1003509-Settasatian1">[93]</xref></td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">6</td>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e019" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1">HDL particle holo-uptake</td>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e020" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1"><xref ref-type="bibr" rid="pcbi.1003509-Moestrup1">[28]</xref>, <xref ref-type="bibr" rid="pcbi.1003509-Martinez1">[29]</xref></td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">7</td>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e021" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1">SR-B1 mediated removal of CE from HDL particles</td>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e022" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1"><xref ref-type="bibr" rid="pcbi.1003509-Rothblat1">[4]</xref>, <xref ref-type="bibr" rid="pcbi.1003509-Rosenson1">[8]</xref>, <xref ref-type="bibr" rid="pcbi.1003509-McAuley1">[18]</xref>, <xref ref-type="bibr" rid="pcbi.1003509-Vergeer1">[36]</xref></td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">8</td>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e023" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1">Synthesis of CE in VLDL</td>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e024" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1"><xref ref-type="bibr" rid="pcbi.1003509-Ouguerram1">[20]</xref>, <xref ref-type="bibr" rid="pcbi.1003509-Schwartz2">[21]</xref></td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">9</td>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e025" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1">Elimination of CE from VLDL</td>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e026" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1"><xref ref-type="bibr" rid="pcbi.1003509-Ouguerram1">[20]</xref>, <xref ref-type="bibr" rid="pcbi.1003509-Schwartz2">[21]</xref></td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">10</td>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e027" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1">Elimination CE from LDL</td>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e028" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1"><xref ref-type="bibr" rid="pcbi.1003509-Ouguerram1">[20]</xref>, <xref ref-type="bibr" rid="pcbi.1003509-Schwartz2">[21]</xref></td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">11</td>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e029" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1">VLDL conversion to LDL via lipolysis</td>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e030" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1"><xref ref-type="bibr" rid="pcbi.1003509-Ouguerram1">[20]</xref></td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">12</td>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e031" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1">CETP mediated CE transfer from HDL to VLDL</td>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e032" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1"><xref ref-type="bibr" rid="pcbi.1003509-Potter1">[13]</xref>, <xref ref-type="bibr" rid="pcbi.1003509-vandePas1">[17]</xref>, <xref ref-type="bibr" rid="pcbi.1003509-McAuley1">[18]</xref>, <xref ref-type="bibr" rid="pcbi.1003509-Ouguerram1">[20]</xref>, <xref ref-type="bibr" rid="pcbi.1003509-Chapman1">[30]</xref></td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">13</td>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e033" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1">CETP mediated CE transfer from HDL to LDL</td>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e034" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1"><xref ref-type="bibr" rid="pcbi.1003509-Potter1">[13]</xref>, <xref ref-type="bibr" rid="pcbi.1003509-Ouguerram1">[20]</xref>, <xref ref-type="bibr" rid="pcbi.1003509-Chapman1">[30]</xref></td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">14</td>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e035" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1">CETP mediated CE transfer from LDL to HDL</td>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e036" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1"><xref ref-type="bibr" rid="pcbi.1003509-Potter1">[13]</xref>, <xref ref-type="bibr" rid="pcbi.1003509-McAuley1">[18]</xref>, <xref ref-type="bibr" rid="pcbi.1003509-Ouguerram1">[20]</xref>, <xref ref-type="bibr" rid="pcbi.1003509-Chapman1">[30]</xref></td>
</tr>
</tbody>
</table>
</alternatives></table-wrap>
<p>The model constants are shown in <xref ref-type="table" rid="pcbi-1003509-t003">Table 3</xref> while the list of parameters are given in <xref ref-type="table" rid="pcbi-1003509-t004">Table 4</xref>; the prior values of parameters and their posterior estimates are discussed in the next section. With the list of reactions given in <xref ref-type="table" rid="pcbi-1003509-t002">Table 2</xref>, the LMK model can be expressed as the following system of ODEs:<disp-formula id="pcbi.1003509.e037"><graphic position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1003509.e037" xlink:type="simple"/><label>(1a)</label></disp-formula><disp-formula id="pcbi.1003509.e038"><graphic position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1003509.e038" xlink:type="simple"/><label>(1b)</label></disp-formula><disp-formula id="pcbi.1003509.e039"><graphic position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1003509.e039" xlink:type="simple"/><label>(1c)</label></disp-formula><disp-formula id="pcbi.1003509.e040"><graphic position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1003509.e040" xlink:type="simple"/><label>(1d)</label></disp-formula><disp-formula id="pcbi.1003509.e041"><graphic position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1003509.e041" xlink:type="simple"/><label>(1e)</label></disp-formula><disp-formula id="pcbi.1003509.e042"><graphic position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1003509.e042" xlink:type="simple"/><label>(1f)</label></disp-formula>One important quantity that the LMK model can help to assess is the rate of <italic>reverse cholesterol transport</italic> (RCT) at the whole-body level. This quantity is thought to play an important role in determining cardiovascular disease risk, but is experimentally challenging to assess. Using the LMK model, we are able to quantify the flux rate of free cholesterol into the nascent disc particles mediated by ABCA1: in particular, this is given by<disp-formula id="pcbi.1003509.e043"><graphic position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1003509.e043" xlink:type="simple"/><label>(2)</label></disp-formula>The term <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e044" xlink:type="simple"/></inline-formula> represents the transformation rate of lipid-poor ApoA-I to nascent discs, which subsequently enter the <italic>α</italic>-HDL pool. The parameter <italic>γ</italic> describes the number of cholesterol molecules per ApoA-I in the nascent discs. <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e045" xlink:type="simple"/></inline-formula> converts the molecular mass of ApoA-I to cholesterol. Finally, the volume of plasma converts RCT rate to the whole-body level: we assume that plasma volume = 3.15 L in a 70 kg adult <xref ref-type="bibr" rid="pcbi.1003509-Chetiveaux1">[22]</xref>. As illustrated in <xref ref-type="fig" rid="pcbi-1003509-g001">Figure 1</xref>, nascent discs are transformed into nascent spheres (as mediated by the LCAT enzyme <xref ref-type="bibr" rid="pcbi.1003509-Chapman1">[30]</xref>) which are assumed to have in their cores <italic>γ</italic> CE molecules per ApoA-I. Hence, the RCT expression (2) also represents the input rate of HDL-CE into the plasma <italic>α</italic>-HDL pool. Note that the factor 2 in the expression for reaction 2 (initiation of RCT) accounts for the assumption that there are 2 ApoA-I molecules per nascent HDL particle.</p>
<table-wrap id="pcbi-1003509-t003" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1003509.t003</object-id><label>Table 3</label><caption>
<title>Model constants.</title>
</caption><alternatives><graphic id="pcbi-1003509-t003-3" position="float" mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1003509.t003" xlink:type="simple"/>
<table><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup>
<thead>
<tr>
<td align="left" rowspan="1" colspan="1">Constant</td>
<td align="left" rowspan="1" colspan="1">Description</td>
<td align="left" rowspan="1" colspan="1">Unit</td>
<td align="left" rowspan="1" colspan="1">Value</td>
<td align="left" rowspan="1" colspan="1">Ref.</td>
</tr>
</thead>
<tbody>
<tr>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e046" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1">Molecular weight of ApoA-I</td>
<td align="left" rowspan="1" colspan="1">g/mol</td>
<td align="left" rowspan="1" colspan="1">28500</td>
<td align="left" rowspan="1" colspan="1"><xref ref-type="bibr" rid="pcbi.1003509-Hbner1">[16]</xref></td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e047" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1">Molecular weight of cholesterol (free and esterified)</td>
<td align="left" rowspan="1" colspan="1">g/mol</td>
<td align="left" rowspan="1" colspan="1">386</td>
<td align="left" rowspan="1" colspan="1"><xref ref-type="bibr" rid="pcbi.1003509-Hbner1">[16]</xref></td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e048" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1">Molecular volume of cholesteryl ester</td>
<td align="left" rowspan="1" colspan="1">Å<sup>3</sup></td>
<td align="left" rowspan="1" colspan="1">1068</td>
<td align="left" rowspan="1" colspan="1"><xref ref-type="bibr" rid="pcbi.1003509-Mazer1">[25]</xref></td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e049" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1">Molecular volume of triglyceride</td>
<td align="left" rowspan="1" colspan="1">Å<sup>3</sup></td>
<td align="left" rowspan="1" colspan="1">1556</td>
<td align="left" rowspan="1" colspan="1"><xref ref-type="bibr" rid="pcbi.1003509-Mazer1">[25]</xref></td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><italic>t</italic></td>
<td align="left" rowspan="1" colspan="1">Thickness of HDL surface</td>
<td align="left" rowspan="1" colspan="1">Å</td>
<td align="left" rowspan="1" colspan="1">20.2</td>
<td align="left" rowspan="1" colspan="1"><xref ref-type="bibr" rid="pcbi.1003509-Mazer1">[25]</xref></td>
</tr>
</tbody>
</table>
</alternatives><table-wrap-foot><fn id="nt101"><label/><p>By convention, the cholesteryl ester mass is measured by quantifying the equivalent mass of free cholesterol.</p></fn></table-wrap-foot></table-wrap><table-wrap id="pcbi-1003509-t004" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1003509.t004</object-id><label>Table 4</label><caption>
<title>Model parameters.</title>
</caption><alternatives><graphic id="pcbi-1003509-t004-4" position="float" mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1003509.t004" xlink:type="simple"/>
<table><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup>
<thead>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">Description</td>
<td align="left" rowspan="1" colspan="1">Unit</td>
</tr>
</thead>
<tbody>
<tr>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e050" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1">Synthesis rate of ApoA-I</td>
<td align="left" rowspan="1" colspan="1">mg/dL/day</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e051" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1">Rate of kidney elimination</td>
<td align="left" rowspan="1" colspan="1">pool/day</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e052" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1">Dissociation rate of excess ApoA-I</td>
<td align="left" rowspan="1" colspan="1">pool/day</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e053" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1">Rate constant in the lipidation of lipid-poor ApoA-I via ABCA1</td>
<td align="left" rowspan="1" colspan="1">pool/day</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><italic>γ</italic></td>
<td align="left" rowspan="1" colspan="1">Stoichiometry of FC to ApoA-I in nascent discs</td>
<td align="left" rowspan="1" colspan="1">unitless</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e054" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1">Rate constant of CE transfer: HDL to VLDL</td>
<td align="left" rowspan="1" colspan="1">pool/day</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e055" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1">Rate constant of CE transfer: HDL to LDL</td>
<td align="left" rowspan="1" colspan="1">pool/day</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e056" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1">Rate constant of CE transfer: LDL to HDL</td>
<td align="left" rowspan="1" colspan="1">pool/day</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e057" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1">Rate constant of CE transfer: VLDL to LDL</td>
<td align="left" rowspan="1" colspan="1">pool/day</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e058" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1">Synthesis rate of CE to VLDL</td>
<td align="left" rowspan="1" colspan="1">mg/dL/day</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e059" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1">Rate constant of CE elimination from VLDL</td>
<td align="left" rowspan="1" colspan="1">pool/day</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e060" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1">Rate constant of CE elimination from LDL</td>
<td align="left" rowspan="1" colspan="1">pool/day</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e061" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1">Rate constant of SRB1-mediated CE elimination from HDL</td>
<td align="left" rowspan="1" colspan="1">pool/day</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e062" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1">Constant contribution to the rate of <italic>α</italic>-HDL holo-particle uptake</td>
<td align="left" rowspan="1" colspan="1">pool/day</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e063" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1">Size-dependent contribution to the rate of <italic>α</italic>-HDL holo-particle uptake</td>
<td align="left" rowspan="1" colspan="1">pool/day/nm</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e064" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1">Parameter governing the particle concentration dependence of fusion rate</td>
<td align="left" rowspan="1" colspan="1">1/(mmol/dL)</td>
</tr>
</tbody>
</table>
</alternatives></table-wrap></sec></sec><sec id="s2b">
<title>Model calibration</title>
<sec id="s2b1">
<title>Parameter estimates: Prior and posterior</title>
<p>The Bayesian approach for parameter estimation is a well established methodology which has found applications in various fields of science <xref ref-type="bibr" rid="pcbi.1003509-Aster1">[31]</xref>, including parameter estimation for models of cellular processes <xref ref-type="bibr" rid="pcbi.1003509-Klinke1">[32]</xref>, <xref ref-type="bibr" rid="pcbi.1003509-Eydgahi1">[33]</xref> as well as pharmacokinetics and pharmacodynamics (PK/PD) <xref ref-type="bibr" rid="pcbi.1003509-Gisleskog1">[34]</xref>, <xref ref-type="bibr" rid="pcbi.1003509-Jonsson1">[35]</xref>. Under this framework, it is assumed that a prior distribution is available for (some) parameters as a result of previous experimental studies. In combination with calibration data, the posterior distribution for the parameters is obtained.</p>
<p>For most of the LMK model parameters, prior estimates are available from literature studies; a detailed discussion of the references from which parameter estimates and their uncertainties are obtained is given in the <xref ref-type="sec" rid="s3">Methods</xref> section. Using the model calibration procedure as discussed in the <xref ref-type="sec" rid="s3">Methods</xref> section, the prior is combined with calibration data to give rise to the posterior estimates. A list of the prior and posterior values of parameters is given in <xref ref-type="table" rid="pcbi-1003509-t005">Table 5</xref>. It is worthwhile noting that, for the most part, the <italic>maximum a posteriori</italic> (MAP) estimate obtained by the calibration process does not depart significantly from the prior. This indicates that the calibration data are fairly consistent with the prior estimates. One exception is the parameter <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e065" xlink:type="simple"/></inline-formula>, which is increased significantly from its prior beyond the 1 SD value. This result is in agreement with experimental evidence that SRB1 plays a significant role in mediating HDL-CE removal from HDL particles <xref ref-type="bibr" rid="pcbi.1003509-Vergeer1">[36]</xref>, in contrast to the expectation of a previous tracer kinetics study <xref ref-type="bibr" rid="pcbi.1003509-Schwartz2">[21]</xref>. The discrepancy may be attributed to the limitation of tracer kinetics studies (for instance, <xref ref-type="bibr" rid="pcbi.1003509-Schwartz2">[21]</xref>) to be able to fully identify the SRB1 contribution. Finally, it can be seen that the calibration data are sufficiently informative to allow relatively precise estimates for the parameters <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e066" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e067" xlink:type="simple"/></inline-formula>, for which there was no prior information. It is worth noting the negative sign in the estimate for <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e068" xlink:type="simple"/></inline-formula>, which implies that the <italic>α</italic>-HDL holo-particle uptake rate decreases with particle size. The sign of this size-dependence is consistent with the hepatic endocytic receptor (mitochondrial ATP synthase subunit <italic>β</italic>) having a higher affinity for the (smaller) HDL-3 as compared to the (larger) HDL-2 <xref ref-type="bibr" rid="pcbi.1003509-Martinez1">[29]</xref>, <xref ref-type="bibr" rid="pcbi.1003509-Vaziri1">[37]</xref>, <xref ref-type="bibr" rid="pcbi.1003509-Fabre1">[38]</xref>.</p>
<table-wrap id="pcbi-1003509-t005" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1003509.t005</object-id><label>Table 5</label><caption>
<title>Prior and posterior estimates of model parameters corresponding to the “nominal subject.”</title>
</caption><alternatives><graphic id="pcbi-1003509-t005-5" position="float" mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1003509.t005" xlink:type="simple"/>
<table><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup>
<thead>
<tr>
<td align="left" rowspan="1" colspan="1">Parameter</td>
<td align="left" rowspan="1" colspan="1">Prior (mean±SD)</td>
<td align="left" rowspan="1" colspan="1">Posterior (mean±SD)</td>
</tr>
</thead>
<tbody>
<tr>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e069" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1">27.44±1.18</td>
<td align="left" rowspan="1" colspan="1">28.46±1.13</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e070" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1">5.19±2.60</td>
<td align="left" rowspan="1" colspan="1">2.42±0.78</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e071" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1">174±312</td>
<td align="left" rowspan="1" colspan="1">170±191</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e072" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1">96.24±17.55</td>
<td align="left" rowspan="1" colspan="1">95.18±15.73</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><italic>γ</italic></td>
<td align="left" rowspan="1" colspan="1">7.55±3.94</td>
<td align="left" rowspan="1" colspan="1">10.17±2.19</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e073" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1">1.47±0.58</td>
<td align="left" rowspan="1" colspan="1">1.49±0.24</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e074" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1">5.47±2.05</td>
<td align="left" rowspan="1" colspan="1">6.92±0.81</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e075" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1">1.98±0.70</td>
<td align="left" rowspan="1" colspan="1">2.89±0.34</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e076" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1">7.52±0.94</td>
<td align="left" rowspan="1" colspan="1">7.70±0.84</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e077" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1">0.96±0.46</td>
<td align="left" rowspan="1" colspan="1">1.50±0.45</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e078" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1">0.88±0.37</td>
<td align="left" rowspan="1" colspan="1">1.30±0.35</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e079" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1">0.67±0.08</td>
<td align="left" rowspan="1" colspan="1">0.64±0.07</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e080" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1">0.31±0.12</td>
<td align="left" rowspan="1" colspan="1">0.60±0.08</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e081" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1">0.14±0.026</td>
<td align="left" rowspan="1" colspan="1">0.13±0.022</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e082" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1">0</td>
<td align="left" rowspan="1" colspan="1">−0.016±0.004</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e083" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1">0</td>
<td align="left" rowspan="1" colspan="1">5000±1544</td>
</tr>
</tbody>
</table>
</alternatives><table-wrap-foot><fn id="nt102"><label/><p>The prior parameter values were estimated from literature as discussed under the <xref ref-type="sec" rid="s3">Methods</xref> section. The SDs of the posterior distribution were estimated using the Fisher Information Matrix.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s2b2">
<title>Calibration data and model explanatory power</title>
<p>In order to identify parameter values using the Bayesian approach, calibration data are needed. However, the choice of calibration data should be made not only for the purpose of quantifying parameters, but also with the consideration for the potential utility and the explanatory power of the model. More specifically, choosing the right types of calibration data can help to increase confidence in a model's predictions of specific scenarios; in addition, model calibration is also an opportunity to test if the model structure, together with prior information on the parameter values, can explain important features of the system being studied.</p>
<p>In our current work, the LMK model was used to explain the effects of CETP inhibition on ApoA-I level as well as the inverse relationship between the FCR of ApoA-I and particle size. Based on this, the calibration data were chosen. In <xref ref-type="fig" rid="pcbi-1003509-g002">Figures 2</xref>, <xref ref-type="fig" rid="pcbi-1003509-g003">3</xref> and <xref ref-type="fig" rid="pcbi-1003509-g004">4</xref> we show the calibration data superimposed with the model simulation, using the <italic>maximum a posteriori</italic> parameter set identified by the calibration procedure (as described in the <xref ref-type="sec" rid="s3">Methods</xref> section). In <xref ref-type="fig" rid="pcbi-1003509-g002">Figure 2</xref>, the decrease in CETP level from 100% to 0% of the nominal subject was simulated by decreasing the three parameters associated with CETP activity <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e084" xlink:type="simple"/></inline-formula> by the same factor. In particular, panels A and B show that the rise in HDL-C (the concentration of HDL-C is computed by summing <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e085" xlink:type="simple"/></inline-formula> and free cholesterol pool, as discussed in the <xref ref-type="sec" rid="s3">Methods</xref> section) and ApoA-I in heterozygotes and homozygotes with CETP deficiency are fairly well captured by the LMK model; the main discrepancy is the under-prediction of HDL-C for CETP heterozygotes. To our knowledge, the increase in ApoA-I under CETP deficiency or inhibition has not yet been explained by existing models: by incorporating the geometric ideas proposed in <xref ref-type="bibr" rid="pcbi.1003509-Mazer1">[25]</xref> the LMK model provides, for the first time, a way to connect the metabolism of ApoA-I and HDL-C. We remark that the LMK model is focused on HDL rather than the metabolism of ApoB-containing particles, which include LDL and VLDL. In particular, the LMK model predicts negligible concentrations of LDL-CE and VLDL-CE in CETP homozygotes, which are inconsistent with the reported concentrations in these subjects <xref ref-type="bibr" rid="pcbi.1003509-Ritsch1">[39]</xref>–<xref ref-type="bibr" rid="pcbi.1003509-Teh1">[41]</xref>. We believe that this discrepancy between the LMK model prediction and reality is due to <italic>β</italic>-LCAT activity <xref ref-type="bibr" rid="pcbi.1003509-Carlson1">[42]</xref>, which in CETP homozygotes could compensate for the lack of CE influx from HDL particles by converting free cholesterol on the surface of ApoB-containing particles into cholesteryl ester. Finally, <xref ref-type="fig" rid="pcbi-1003509-g003">Figure 3</xref> shows that the CE fluxes in the LMK model are consistent with the values measured <xref ref-type="bibr" rid="pcbi.1003509-Ouguerram1">[20]</xref>, in particular the CE flux from HDL to LDL is close to that from LDL to HDL.</p>
<fig id="pcbi-1003509-g002" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1003509.g002</object-id><label>Figure 2</label><caption>
<title>The fit of the model to the calibration data for CETP deficiency: HDL-C (panel A), ApoA-I (panel B), LDL-CE (panel C) and VLDL-CE (panel D).</title>
<p>The data are as shown in <xref ref-type="table" rid="pcbi-1003509-t006">Table 6</xref>, obtained by pooling HDL-C and ApoA-I data from references <xref ref-type="bibr" rid="pcbi.1003509-Inazu1">[81]</xref>–<xref ref-type="bibr" rid="pcbi.1003509-Asztalos4">[83]</xref> and LDL-CE, VLDL-CE data from references <xref ref-type="bibr" rid="pcbi.1003509-Ouguerram1">[20]</xref>, <xref ref-type="bibr" rid="pcbi.1003509-Schwartz2">[21]</xref>. The model simulation curves were obtained by decreasing the 3 parameters representing CETP activity <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e086" xlink:type="simple"/></inline-formula> from 100% to 0% of those corresponding to the nominal subject.</p>
</caption><graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1003509.g002" position="float" xlink:type="simple"/></fig><fig id="pcbi-1003509-g003" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1003509.g003</object-id><label>Figure 3</label><caption>
<title>The fit of the model to the calibration data: CE fluxes.</title>
<p>The data are as shown in <xref ref-type="table" rid="pcbi-1003509-t008">Table 8</xref>, taken from reference <xref ref-type="bibr" rid="pcbi.1003509-Ouguerram1">[20]</xref>. The model simulation is produced using the point estimate of parameters for the nominal subject.</p>
</caption><graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1003509.g003" position="float" xlink:type="simple"/></fig><fig id="pcbi-1003509-g004" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1003509.g004</object-id><label>Figure 4</label><caption>
<title>The fit of the model to the calibration data: FCR of ApoA-I versus HDL-C/ApoA-I ratio.</title>
<p>The data sources are: Brinton <italic>et al</italic> <xref ref-type="bibr" rid="pcbi.1003509-Brinton1">[43]</xref>, Ikewaki <italic>et al</italic> <xref ref-type="bibr" rid="pcbi.1003509-Ikewaki2">[45]</xref>, Schaefer <italic>et al</italic> <xref ref-type="bibr" rid="pcbi.1003509-Schaefer1">[44]</xref>. The piecewise linear fit and the confidence interval are discussed in the <xref ref-type="sec" rid="s3">Methods</xref> section. The model simulation values are indicated by asterisk symbols, for the nominal subject and the heterozygote, homozygote of CETP mutation.</p>
</caption><graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1003509.g004" position="float" xlink:type="simple"/></fig>
<p>Another important and robust finding that has been observed in HDL metabolism is the relationship between FCR of ApoA-I and particle size (estimated using a surrogate measure) seen in normal subjects <xref ref-type="bibr" rid="pcbi.1003509-Brinton1">[43]</xref>, <xref ref-type="bibr" rid="pcbi.1003509-Schaefer1">[44]</xref>; in addition, heterozygotes and homozygotes of CETP deficiency are also observed to have a decreased FCR of ApoA-I <xref ref-type="bibr" rid="pcbi.1003509-Ikewaki2">[45]</xref>. Thus, an important objective of the calibration process is to test whether the structure of the model, together with an assumption on the linear size-dependence of HDL holo-particle uptake rate, can explain this relationship. The inverse relationship observed between the FCR of ApoA-I and the ratio HDL-C/ApoA-I (a surrogate measure of HDL size) is shown in <xref ref-type="fig" rid="pcbi-1003509-g004">Figure 4:</xref> in particular, data from Schaefer <italic>et al</italic> <xref ref-type="bibr" rid="pcbi.1003509-Schaefer1">[44]</xref>, Brinton <italic>et al</italic> <xref ref-type="bibr" rid="pcbi.1003509-Brinton1">[43]</xref> and Ikewaki <italic>et al</italic> <xref ref-type="bibr" rid="pcbi.1003509-Ikewaki2">[45]</xref> are given. A linear fit was carried out using the pooled data of Schaefer <italic>et al</italic> <xref ref-type="bibr" rid="pcbi.1003509-Schaefer1">[44]</xref>, Brinton <italic>et al</italic> <xref ref-type="bibr" rid="pcbi.1003509-Brinton1">[43]</xref> and normal subjects from Ikewaki <italic>et al</italic> <xref ref-type="bibr" rid="pcbi.1003509-Ikewaki2">[45]</xref>, with the mean shown as a dashed pink line and the 1 SD confidence region shown as dashed black lines in <xref ref-type="fig" rid="pcbi-1003509-g004">Figure 4</xref>. The ApoA-I FCR for CETP homozygotes (who have large HDL particles) are assumed to be the lowest level attainable, hence this value was taken as the “floor” of the fit. The LMK model was calibrated to the piecewise linear relationship represented by the pink line and <xref ref-type="fig" rid="pcbi-1003509-g004">Figure 4</xref> shows that simulations for normal and CETP mutation subjects (denoted by the asterisk symbols) are all in good agreement with the inverse relationship. The LMK model reproduces the dependence of ApoA-I FCR on CETP primarily by changing the distribution of ApoA-I between the lipid-poor and <italic>α</italic>-HDL pools (which have different clearance rates), with a minor contribution from the explicit size dependence of holo-particle uptake, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e087" xlink:type="simple"/></inline-formula>.</p>
</sec></sec><sec id="s2c">
<title>Model validation</title>
<p>In order to increase confidence in its predictions, the LMK model has been validated by simulating a number of scenarios that have not been used in the calibration process. In particular, since ABCA1 and ApoA-I are important targets in the pathway, the literature data on subjects with mutations in these genes <xref ref-type="bibr" rid="pcbi.1003509-Asztalos1">[46]</xref>, <xref ref-type="bibr" rid="pcbi.1003509-Santos1">[47]</xref> are compared against the model simulations. The heterozygotes and homozygotes of ABCA1 mutation are simulated by setting <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e088" xlink:type="simple"/></inline-formula> (representing ABCA1 activity) to 50% and 0% of its nominal value respectively; similarly, heterozygotes and homozygotes of ApoA-I mutation are simulated by setting the parameter <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e089" xlink:type="simple"/></inline-formula> (representing ApoA-I synthesis rate) to 50% and 0% of its nominal value respectively. <xref ref-type="fig" rid="pcbi-1003509-g005">Figure 5</xref> shows the mean and 95% confidence intervals of the model simulations, compared to the literature data (mean and SD are given). An examination of the results for the heterozygotes shows that, encouragingly, the LMK model is able to differentiate between the effects of ABCA1 and ApoA-I mutations on HDL-C and ApoA-I levels: both quantities decrease more for ApoA-I heterozygotes as compared to ABCA1 heterozygotes. Furthermore, the LMK model predicts that heterozygotes of ABCA1 mutation have smaller HDL particles (data not shown), consistent with the data of Asztalos <italic>et al</italic> <xref ref-type="bibr" rid="pcbi.1003509-Asztalos1">[46]</xref>.</p>
<fig id="pcbi-1003509-g005" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1003509.g005</object-id><label>Figure 5</label><caption>
<title>Model validation: simulation of ABCA1 and ApoA-I mutations compared with literature data for HDL-C (panel A) and ApoA-I (panel B).</title>
<p>For the simulation results, the mean and the 95% confidence intervals are plotted. The data sources are Asztalos <italic>et al</italic> <xref ref-type="bibr" rid="pcbi.1003509-Asztalos1">[46]</xref> and Santos <italic>et al</italic> <xref ref-type="bibr" rid="pcbi.1003509-Santos1">[47]</xref>; the mean ± SD are shown. The model simulations of the mutation cases were obtained by taking the parameter values for the nominal subject and set <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e090" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e091" xlink:type="simple"/></inline-formula> to 50% and 0% of the nominal values respectively.</p>
</caption><graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1003509.g005" position="float" xlink:type="simple"/></fig>
<p>Most of the calibration data are static in nature, hence it is of particular interest to perform dynamic simulations of the LMK model and compare them to existing data. As a validation, we would like to see if the LMK model reproduces the characteristic biphasic decay curves seen in tracer kinetic experiments with labelled ApoA-I. In the LMK model, the injection of radio-labelled dose is represented by a small addition to the pool of lipid-poor ApoA-I and the fractional dose remaining in the sum of the two pools of ApoA-I is plotted; refer to the <xref ref-type="sec" rid="s3">Methods</xref> section for the details of the simulation methodology. This is simulated using the parameters identified for the nominal subject and the result is shown in <xref ref-type="fig" rid="pcbi-1003509-g006">Figure 6:</xref> it can be seen that the simulated decay curve is biphasic and similar to the data obtained by digitizing <xref ref-type="fig" rid="pcbi-1003509-g003">Figure 3</xref> of Ikewaki <italic>et al</italic> <xref ref-type="bibr" rid="pcbi.1003509-Ikewaki3">[48]</xref>. Furthermore, the mean residence time (which is the inverse of FCR) of labelled ApoA-I computed from the model simulation is 4.2 days, which is in good agreement with the result of 4.8±0.3 days as measured in 4 subjects by Ikewaki <italic>et al</italic> <xref ref-type="bibr" rid="pcbi.1003509-Ikewaki3">[48]</xref>.</p>
<fig id="pcbi-1003509-g006" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1003509.g006</object-id><label>Figure 6</label><caption>
<title>Model validation: Simulation of tracer kinetic experiment with labelled ApoA-I compared to experimental data.</title>
<p>The data are obtained by digitization of tracer kinetics measurements carried out in 4 subjects and shown in <xref ref-type="fig" rid="pcbi-1003509-g003">Figure 3</xref> of Ikewaki <italic>et al</italic> <xref ref-type="bibr" rid="pcbi.1003509-Ikewaki3">[48]</xref>. The model simulation corresponds to the nominal subject.</p>
</caption><graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1003509.g006" position="float" xlink:type="simple"/></fig></sec><sec id="s2d">
<title>Explaining epidemiological relationship using a virtual population</title>
<p>Having calibrated and validated the LMK model, we use it as a platform for exploring the observed epidemiological relationship between HDL-C and CVD risk. For this purpose, a virtual population is generated in a manner analogous to that of reference <xref ref-type="bibr" rid="pcbi.1003509-Moss1">[49]</xref>. In particular, model parameters are sampled from a multivariate normal distribution and for each set of parameters the “phenotype” of the corresponding virtual subject is simulated using the LMK model. As there is no information available on the correlation between model parameters in a real population, we have assumed them to be uncorrelated and each is drawn from a normal distribution with a relative SD = 15% around the value corresponding to the posterior values for the nominal subject (see <xref ref-type="table" rid="pcbi-1003509-t005">Table 5</xref>).</p>
<p>Despite the fact that the parameter distribution in the virtual population is uncorrelated, some of the simulation outputs show significant correlations as a result of the model structure. Of particular interest is the correlation between RCT rate (as defined in (2)) and plasma biomarkers. Shown in <xref ref-type="fig" rid="pcbi-1003509-g007">Figure 7</xref> is the relationship between RCT rate and HDL-C within the virtual population: it can be seen that there is a surprisingly strong correlation between the two quantities (<italic>r</italic> = 0.95). We note that the RCT rate given in (2) corresponds to the input rate of HDL-CE into plasma: in fact, the plasma concentration of HDL-CE can be expressed as the following:<disp-formula id="pcbi.1003509.e092"><graphic position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1003509.e092" xlink:type="simple"/><label>(3)</label></disp-formula>where the clearance is defined as the plasma volume multiplied by the sum of elimination rate constants. In the LMK model, elimination processes for HDL-CE include those mediated by CETP and SRB1, as well as the holo-particle uptake. While the RCT rate shows a strong correlation with HDL-C, we see that in <xref ref-type="fig" rid="pcbi-1003509-g008">Figure 8</xref> the clearance of HDL-CE shows a much weaker negative correlation with HDL-C (<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e093" xlink:type="simple"/></inline-formula>). Hence, the simulation results suggest that the variation in HDL-C within the virtual population is largely attributed to variations in the RCT rate and not due to its clearance. Under the “HDL flux hypothesis” <xref ref-type="bibr" rid="pcbi.1003509-Larach1">[2]</xref> that low RCT rate results in high CVD risk, the relationship shown in <xref ref-type="fig" rid="pcbi-1003509-g007">Figure 7</xref> provides a plausible explanation for the epidemiological association between HDL-C and CVD risk. The same set of virtual subjects is also used in subsequent sections for target evaluation and biomarker identification.</p>
<fig id="pcbi-1003509-g007" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1003509.g007</object-id><label>Figure 7</label><caption>
<title>The distribution of RCT rate and HDL-C and their correlation in the simulated virtual population.</title>
<p>By drawing the parameters of the model from an uncorrelated, multivariate normal distribution, a set of 2000 virtual patients is generated and the model simulations of RCT rate and HDL-C are shown. The right-hand axis represents the hypothetical inverse relationship between RCT rate and CVD risk.</p>
</caption><graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1003509.g007" position="float" xlink:type="simple"/></fig><fig id="pcbi-1003509-g008" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1003509.g008</object-id><label>Figure 8</label><caption>
<title>The distribution of the clearance of HDL-CE and HDL-C and their correlation in the simulated virtual population.</title>
<p>By drawing the parameters of the model from an uncorrelated, multivariate normal distribution, a set of 2000 virtual patients is generated and the model simulations of HDL-CE clearance rate and HDL-C are shown.</p>
</caption><graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1003509.g008" position="float" xlink:type="simple"/></fig></sec><sec id="s2e">
<title>HDL-C raising therapies</title>
<p>The LMK model can be used to evaluate actual and potential HDL-C raising therapies, by modulating targets of interest. We have used simulated the model for both the nominal subject, as well as for a virtual population.</p>
<sec id="s2e1">
<title>CETP inhibition</title>
<p>The model predictions of CETP inhibition on the nominal subject, together with 95% confidence intervals, are shown in <xref ref-type="fig" rid="pcbi-1003509-g009">Figure 9</xref>. In alignment with the calibration data, as CETP level decreases both HDL-C and ApoA-I increase strikingly (see panels A and B). These changes are associated with a significant increase in HDL size as well as a small increase in HDL particle concentration (HDL-P) (see panels C and D). Both the absolute concentration of lipid-poor ApoA-I and RCT rate remain essentially unchanged (see panels E and F).</p>
<fig id="pcbi-1003509-g009" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1003509.g009</object-id><label>Figure 9</label><caption>
<title>Model predictions for the dependence of HDL measures (HDL-C, panel A; ApoA-I, panel B; HDL size, panel C; HDL particle concentration, panel D; lipid-poor ApoA-I, panel E) and RCT (panel F) on the CETP level.</title>
<p>The model simulation curves were obtained by decreasing the 3 parameters associated with CETP activity <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e094" xlink:type="simple"/></inline-formula> from 100% to 0% of those corresponding to the nominal subject. For each prediction, the mean and the 95% confidence intervals are plotted.</p>
</caption><graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1003509.g009" position="float" xlink:type="simple"/></fig>
<p>To further illustrate the effect of CETP inhibition, in <xref ref-type="fig" rid="pcbi-1003509-g010">Figure 10</xref> we simulate the therapy in a virtual population. In particular, we select subjects with low HDL-C (40 mg/dL or less) for treatment with a hypothetical drug that inhibits the plasma CETP by 80% and simulate the changes in HDL-C and RCT rate in the treated subjects. It can be seen that the rise in HDL-C does not correspond to an increase in RCT rate. In fact, the effects induced by CETP inhibition depart from the baseline relationship. This is an illustration of a target impacting a biomarker which is correlated but not causally linked with the disease mechanism: the hypothetical drug does not bring about a therapeutic effect of increasing RCT rate despite increasing HDL-C. However, there could be a potential CV benefit due to a small (14%) decrease in LDL-C (data not shown).</p>
<fig id="pcbi-1003509-g010" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1003509.g010</object-id><label>Figure 10</label><caption>
<title>Simulation of CETP inhibition on a virtual population with low HDL-C (≤40 mg/dL).</title>
<p>Each virtual patient selected for the treatment simulation had its rate constants associated with CETP activity <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e095" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e096" xlink:type="simple"/></inline-formula> decreased to 20% of their original values.</p>
</caption><graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1003509.g010" position="float" xlink:type="simple"/></fig></sec><sec id="s2e2">
<title>ABCA1 up-regulation</title>
<p>The model predictions for ABCA1 up-regulation on the nominal subject, together with 95% confidence intervals, are shown in <xref ref-type="fig" rid="pcbi-1003509-g011">Figure 11</xref>. The simulation results show that as ABCA1 activity increases, both HDL-C and ApoA-I increases (see panels A and B). Panels C and D of <xref ref-type="fig" rid="pcbi-1003509-g011">Figure 11</xref> show that these increases reflect not only an increase in HDL size, but also increases in particle concentration. In stark contrast to CETP inhibition, under ABCA1 upregulation the RCT rate is predicted to increase markedly (panel E) and the absolute concentration of lipid-poor ApoA-I decreases.</p>
<fig id="pcbi-1003509-g011" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1003509.g011</object-id><label>Figure 11</label><caption>
<title>Model predictions for the dependence of HDL measures (HDL-C, panel A; ApoA-I, panel B; HDL size, panel C; HDL particle concentration, panel D; lipid-poor ApoA-I, panel E) and RCT (panel F) on ABCA1 activity.</title>
<p>The model simulation curves were obtained by increasing the parameter representing ABCA1 activity <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e097" xlink:type="simple"/></inline-formula> from 100% to 300% of the nominal subject. For each prediction, the mean and the 95% confidence intervals are plotted.</p>
</caption><graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1003509.g011" position="float" xlink:type="simple"/></fig>
<p>We next consider ABCA1 up-regulation for the virtual population as shown in <xref ref-type="fig" rid="pcbi-1003509-g007">Figure 7</xref>. In particular, we select the same subjects with low HDL-C as was previously chosen for CETP inhibition. We simulate a hypothetical drug that increases ABCA1 activity in each of the treated subjects by 100% and examine the changes in HDL-C and RCT rate. As shown in <xref ref-type="fig" rid="pcbi-1003509-g012">Figure 12</xref>, under ABCA1 up-regulation both HDL-C and RCT rate increase. In particular, the changes induced by ABCA1 up-regulation are predicted to follow the baseline epidemiological relationship.</p>
<fig id="pcbi-1003509-g012" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1003509.g012</object-id><label>Figure 12</label><caption>
<title>Simulation of ABCA1 up-regulation on a virtual population with low HDL-C (≤40 mg/dL).</title>
<p>Each virtual patient seleted for the treatment simulation had its ABCA1 activity (<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e098" xlink:type="simple"/></inline-formula>) increased by 100% of its initial value.</p>
</caption><graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1003509.g012" position="float" xlink:type="simple"/></fig>
<p>In order to further elaborate on the differences between the two target modulations, we compare in <xref ref-type="fig" rid="pcbi-1003509-g013">Figure 13</xref> the changes in biomarkers for CETP inhibition and ABCA1 up-regulation. The simulation results show that for a given fold change in HDL-C, CETP inhibition gives rise to larger particle sizes but fewer particle numbers as compared to ABCA1 up-regulation. Due to the differences in the particle size and number under the two target modulations, for a given fold-change in HDL-C, ApoA-I is predicted to increase more under ABCA1 up-regulation as compared to CETP inhibition. Reassuringly, the simulated increases in ApoA-I for CETP inhibition are in fair agreement with literature data for the three CETP inhibitors, Dalcetrapib <xref ref-type="bibr" rid="pcbi.1003509-Schwartz3">[50]</xref>, Torcetrapib <xref ref-type="bibr" rid="pcbi.1003509-Clark1">[51]</xref> and Anacetrapib <xref ref-type="bibr" rid="pcbi.1003509-Cannon1">[52]</xref>. For CETP inhibition the predicted decline in LDL-C as the fold-change in HDL-C increases is in good agreement with data on the three CETP inhibitors (<xref ref-type="fig" rid="pcbi-1003509-g013">Figure 13</xref>, panel E). Conversely for ABCA1 up-regulation the LMK model predicts an increase in LDL-C with increasing fold-change in HDL-C. This finding is a consequence of the first-order CETP-mediated transfer processes between HDL, VLDL and LDL particles. It is qualitatively consistent with the GWAS study of Voight <italic>et al</italic> <xref ref-type="bibr" rid="pcbi.1003509-Voight1">[53]</xref> which showed that ABCA1 SNP rs3890182 raised HDL-C and LDL-C by comparable amounts.</p>
<fig id="pcbi-1003509-g013" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1003509.g013</object-id><label>Figure 13</label><caption>
<title>Comparison of CETP inhibition with ABCA1 up-regulation: changes in RCT rate (panel A) and biomarkers (ApoA-I, panel B; HDL size, panel C; HDL particle concentration, panel D; LDL-C, panel E) versus the rise in HDL-C.</title>
<p>The nominal subject is taken as the baseline. The model simulation of CETP inhibition is compared with literature data of CETP inhibitors, Dalcetrapib <xref ref-type="bibr" rid="pcbi.1003509-Schwartz3">[50]</xref>, Torcetrapib <xref ref-type="bibr" rid="pcbi.1003509-Clark1">[51]</xref> and Anacetrapib <xref ref-type="bibr" rid="pcbi.1003509-Cannon1">[52]</xref>.</p>
</caption><graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1003509.g013" position="float" xlink:type="simple"/></fig></sec></sec><sec id="s2f">
<title>Lipoprotein biomarkers</title>
<p>A number of studies have shown that CVD risk is correlated with plasma biomarkers such as HDL-C <xref ref-type="bibr" rid="pcbi.1003509-DiAngelantonio1">[1]</xref>, HDL-P <xref ref-type="bibr" rid="pcbi.1003509-Mackey1">[54]</xref> and pre-<italic>β</italic><sub>1</sub> <xref ref-type="bibr" rid="pcbi.1003509-Sethi1">[55]</xref>, <xref ref-type="bibr" rid="pcbi.1003509-Kane1">[56]</xref> levels. In addition, the combination of NMR analysis of HDL with genotyping has also given a glimpse into the possible genes associated with HDL particle measures <xref ref-type="bibr" rid="pcbi.1003509-Kaess1">[57]</xref>. However, the mechanistic basis for these experimental observations as well as what underlies the correlations between the plasma biomarkers are not well understood. Using the proposed LMK model, we can reproduce and explain the correlations between these plasma biomarkers.</p>
<p>In addressing these questions, the simulated biomarkers within the population of 2000 virtual patients (as previously shown in <xref ref-type="fig" rid="pcbi-1003509-g007">Figure 7</xref>) were studied. The correlation between HDL-P and HDL-C within this set of virtual patients (<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e099" xlink:type="simple"/></inline-formula>) is shown in <xref ref-type="fig" rid="pcbi-1003509-g014">Figure 14</xref>, panel A; we see that the simulation result is qualitatively similar to the positive correlation shown by Mackey <italic>et al</italic> <xref ref-type="bibr" rid="pcbi.1003509-Mackey1">[54]</xref> (the absolute values of HDL-P obtained by NMR are approximately 2-fold greater than our simulations which are based on the updated Shen model; the discrepancy is discussed in <xref ref-type="bibr" rid="pcbi.1003509-Mazer1">[25]</xref>). A positive correlation also exists in the virtual population between HDL size and HDL-C (<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e100" xlink:type="simple"/></inline-formula>), consistent with Mackey <italic>et al</italic> <xref ref-type="bibr" rid="pcbi.1003509-Mackey1">[54]</xref> (see <xref ref-type="fig" rid="pcbi-1003509-g014">Figure 14</xref>, panel B).</p>
<fig id="pcbi-1003509-g014" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1003509.g014</object-id><label>Figure 14</label><caption>
<title>Correlations between HDL-C and HDL-P (panel A), and HDL-C and HDL size (panel B) in a virtual population of 2000 subjects.</title>
</caption><graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1003509.g014" position="float" xlink:type="simple"/></fig>
<p>Due to the growing appreciation for the importance of RCT <xref ref-type="bibr" rid="pcbi.1003509-Larach1">[2]</xref>, <xref ref-type="bibr" rid="pcbi.1003509-Rosenson1">[8]</xref>, <xref ref-type="bibr" rid="pcbi.1003509-Rothblat2">[58]</xref>, there are on-going efforts in trying to quantitatively assess the steps involved in the process. The ABCA1 transporter is involved in the first step of RCT by removing cholesterol from peripheral tissues to plasma and its activity level in patients has been studied <xref ref-type="bibr" rid="pcbi.1003509-Patel1">[59]</xref>. In particular, ABCA1 gene expression and protein concentration on leukocytes has been measured in patients with type 2 diabetes, where the data suggested a negative correlation between ABCA1 expression and HbA1c levels <xref ref-type="bibr" rid="pcbi.1003509-Patel1">[59]</xref>. While there are assays that can quantify ABCA1 protein levels in specific cell types <xref ref-type="bibr" rid="pcbi.1003509-Paul1">[60]</xref>, an experimental technique for the assessment of ABCA1 activity <italic>in-vivo</italic> at the whole body level has yet to be developed. Given the current experimental limitations, there is an interest to evaluate the potential effectiveness of plasma-based biomarkers for quantitatively assessing ABCA1 activity.</p>
<p>Using the LMK model, we evaluated the potential effectiveness of two biomarkers for ABCA1 activity: firstly, the absolute concentration of lipid-poor ApoA-I; secondly, the relative concentration of lipid-poor ApoA-I as the percentage of total ApoA-I. <xref ref-type="fig" rid="pcbi-1003509-g015">Figure 15</xref> panel A shows that the former is only weakly correlated with ABCA1 activity. In contrast, panel B shows that the latter exhibits a strong inverse correlation with ABCA1 activity; in fact, given a measured value of % lipid-poor ApoA-I, the relationship can be used to estimate ABCA1 activity. This result can be better understood by the following analysis. From <xref ref-type="disp-formula" rid="pcbi.1003509.e037">equation (1a)</xref>, the absolute concentration of lipid-poor ApoA-I at steady state can be expressed as:<disp-formula id="pcbi.1003509.e101"><graphic position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1003509.e101" xlink:type="simple"/><label>(4a)</label></disp-formula><disp-formula id="pcbi.1003509.e102"><graphic position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1003509.e102" xlink:type="simple"/><label>(4b)</label></disp-formula>On the other hand, from (1b) the % lipid-poor ApoA-I can be expressed as the following:<disp-formula id="pcbi.1003509.e103"><graphic position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1003509.e103" xlink:type="simple"/><label>(5a)</label></disp-formula><disp-formula id="pcbi.1003509.e104"><graphic position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1003509.e104" xlink:type="simple"/><label>(5b)</label></disp-formula>Comparison of the denominators in (4a) and (5a) show that in the former expression, an additional parameter <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e105" xlink:type="simple"/></inline-formula> enters; however, it is small compared to <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e106" xlink:type="simple"/></inline-formula> (the mean values being 2.42 and 95.18 respectively; see <xref ref-type="table" rid="pcbi-1003509-t005">Table 5</xref>). In the numerator, the main quantitative difference between the two expressions is the remodeling flux, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e107" xlink:type="simple"/></inline-formula>, versus the ApoA-I normalized flux, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e108" xlink:type="simple"/></inline-formula>. As shown in <xref ref-type="fig" rid="pcbi-1003509-g016">Figure 16</xref>, the latter has a flatter dependence on <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e109" xlink:type="simple"/></inline-formula> as well as less variability due to other parameters. As a result, the ratio <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e110" xlink:type="simple"/></inline-formula> allows for a more precise estimate of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e111" xlink:type="simple"/></inline-formula> compared to <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e112" xlink:type="simple"/></inline-formula> above. In conclusion, the analysis shows that the stronger inverse relationship shown in <xref ref-type="fig" rid="pcbi-1003509-g015">Figure 15</xref> panel B can be attributed to the normalization of the remodeling flux by ApoA-I.</p>
<fig id="pcbi-1003509-g015" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1003509.g015</object-id><label>Figure 15</label><caption>
<title>Correlations between <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e113" xlink:type="simple"/></inline-formula> and absolute concentration of lipid-poor ApoA-I (panel A), and between <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e114" xlink:type="simple"/></inline-formula> and % lipid-poor ApoA-I (panel B) in a virtual population of 2000 subjects.</title>
</caption><graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1003509.g015" position="float" xlink:type="simple"/></fig><fig id="pcbi-1003509-g016" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1003509.g016</object-id><label>Figure 16</label><caption>
<title>Comparison of two expressions involving remodeling flux: <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e115" xlink:type="simple"/></inline-formula> (panel A) and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e116" xlink:type="simple"/></inline-formula> (panel B).</title>
<p>The distributions of absolute and ApoA-I adjusted remodeling flux in the virtual population are plotted against <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e117" xlink:type="simple"/></inline-formula>. The simulations of the nominal subject with only the parameter <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e118" xlink:type="simple"/></inline-formula> varied are shown as solid lines.</p>
</caption><graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1003509.g016" position="float" xlink:type="simple"/></fig>
<p>The simulation results may further explain why, in some literature studies, % lipid-poor ApoA-I (note that the absolute concentration of lipid-poor ApoA-I can be experimentally estimated by assays that measure pre-<italic>β</italic><sub>1</sub> <xref ref-type="bibr" rid="pcbi.1003509-Nanjee1">[61]</xref>) has been proposed as a risk factor, as well as how increased % lipid-poor ApoA-I could be associated with CVD risk. Our proposal of using the % lipid-poor ApoA-I as a surrogate measure for ABCA1 activity is in concordance with the previous suggestion by Asztalos <italic>et al</italic> <xref ref-type="bibr" rid="pcbi.1003509-Asztalos2">[62]</xref> that the ratio pre-<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e119" xlink:type="simple"/></inline-formula> is a measure of the efficiency of RCT: a decrease in this ratio has been thought to reflect an enhanced RCT <xref ref-type="bibr" rid="pcbi.1003509-Asztalos2">[62]</xref>, <xref ref-type="bibr" rid="pcbi.1003509-Asztalos3">[63]</xref>. In addition, our finding of the inverse correlation between % lipid-poor ApoA-I and ABCA1 activity may explain the observation that increased fractional pre-<italic>β</italic><sub>1</sub> is associated with increased maximum intima-media thickness in both diabetics <xref ref-type="bibr" rid="pcbi.1003509-Hirayama1">[64]</xref> and non-diabetic subjects <xref ref-type="bibr" rid="pcbi.1003509-deVries1">[65]</xref>, as well as being associated with an increased risk for coronary heart disease and myocardial infarctions <xref ref-type="bibr" rid="pcbi.1003509-Guey1">[66]</xref>.</p>
</sec><sec id="s2g">
<title>Future directions</title>
<p>We foresee a number of potential future applications of the LMK model in the context of drug discovery and development, including the following:</p>
<list list-type="order"><list-item>
<p>Confirmation of a molecule's mechanism of action: this can be done by checking the clinically observed changes in lipoprotein measures against the model predictions. This is an important task, since a molecule that increases HDL-C may do so by modulating the RCT pathway not only on its intended target but may also have off-target effects. As the model shows, the choice of mechanism in raising HDL-C could be crucially important for whether or not it brings about cardiovascular benefit.</p>
</list-item><list-item>
<p>Determining the right dosage schedule for maximum cholesterol removal: the LMK model could help to integrate the pharmacokinetics of a molecule with the dynamics of HDL metabolism.</p>
</list-item><list-item>
<p>Evaluating combinations of target modulations: the LMK model could help to address the question of the potential synergism between targets in the RCT pathway.</p>
</list-item><list-item>
<p>Development of personalized health care (PHC) strategy: simulations of the model to generate virtual populations could be used to address the question of which patient subpopulations are most likely to benefit from a given therapy and how those subjects might be selected using plasma-based diagonostic tests.</p>
</list-item></list>
<p>The LMK model is focused on capturing the dynamics of ApoA-I and CE transfers. However, extensions of the model to incorporate ApoA-II dynamics as well as explicitly representing triglyceride and phospholipid metabolism would be important for describing the effects of other drug classes, including the PPAR-<italic>α</italic> and <italic>γ</italic> agonists <xref ref-type="bibr" rid="pcbi.1003509-Shah1">[67]</xref>, <xref ref-type="bibr" rid="pcbi.1003509-Apostoli1">[68]</xref> or synthetic phospholipids <xref ref-type="bibr" rid="pcbi.1003509-Rodrigueza1">[69]</xref>, <xref ref-type="bibr" rid="pcbi.1003509-Tchoua1">[70]</xref>. These remain topics for further research.</p>
</sec><sec id="s2h">
<title>Conclusions</title>
<p>We have developed a novel, <italic>in-silico</italic> model of lipoprotein metabolism focused on the reverse cholesterol transport pathway. The model incorporates important concepts of HDL biology, including the regeneration of lipid-poor ApoA-I via <italic>α</italic>-HDL remodeling processes, and has been calibrated using literature data from a wide variety of sources. The model has been further validated by simulating scenarios not considered in the calibration process. These include its ability to reproduce the levels of HDL-C and ApoA-I in hetero- and homozygous subjects with either ABCA1 or ApoA-I mutation and the observed biphasic kinetics of ApoA-I seen in tracer kinetics studies. This provides an increased confidence in the LMK model predictions with respect to modulations of these important targets and in the model's ability to simulate time-dependent scenarios.</p>
<p>In this paper, we have illustrated the applications of the LMK model in comparing the two target modulations, CETP inhibition and ABCA1 up-regulation. The results drawn from our model provide a possible explanation for the non-efficacy of dalcetrapib in the dal-OUTCOMES trial <xref ref-type="bibr" rid="pcbi.1003509-Schwartz1">[7]</xref> as well as suggesting that ABCA1 is a target that would increase the RCT rate. The model provides predictions on the biomarker changes as a result of ABCA1 target modulation. Furthermore, computational experiments using a virtual population have shown why the % lipid-poor ApoA-I, rather than the absolute concentration of lipid-poor ApoA-I, is a better biomarker for assessing the <italic>in-vivo</italic> ABCA1 activity. By integrating mechanistic concepts and data, the model provides a way to quantitatively evaluate and explore hypotheses of lipoprotein metabolism.</p>
</sec></sec><sec id="s3" sec-type="methods">
<title>Methods</title>
<sec id="s3a">
<title>Model derivation</title>
<sec id="s3a1">
<title>Mass balance considerations</title>
<p>The LMK model (<xref ref-type="fig" rid="pcbi-1003509-g001">Figure 1</xref>) explicitly represents the mass balance of ApoA-I and CE molecules in plasma, whereas the mass balance of FC and PL molecules is represented implicitly. The input of ApoA-I to plasma reflects its synthesis rate, while the elimination of ApoA-I results from the excretion of lipid-poor ApoA-I by the kidney and holo-uptake of <italic>α</italic>-HDL particles by the liver. The remodeling of HDL particles by particle fusion, CETP, SRB1 and other processes leads to the recycling of ApoA-I from <italic>α</italic>-HDL particles to lipid-poor ApoA-I. Recycling influences the kinetics of ApoA-I in plasma but does not affect its mass balance. The input of CE to plasma reflects the rapid esterification of FC molecules in the nascent discs as they are converted to nascent spheres plus a small amount of CE which enters plasma during VLDL synthesis. The rate at which CE molecules appear in the <italic>α</italic>-HDL pool (via the nascent sphere) is defined in the LMK model as the RCT input rate and is assumed to equal the rate at which FC molecules are loaded onto the nascent discs (<xref ref-type="disp-formula" rid="pcbi.1003509.e043">equation (2)</xref>). Elimination of CE from plasma results from holo-uptake and SRB1-mediated uptake of CE from all lipoprotein species. The CETP-mediated transfer of CE between <italic>α</italic>-HDL, VLDL and LDL does not affect the overall mass balance in plasma.</p>
<p>FC and PL molecules are present on the surfaces of all spherical lipoprotein particles in plasma as well as on the membranes of red blood cells (RBCs) and other cells that are in contact with the plasma. Based on Shen€s model of lipoprotein structure (Shen <italic>et al</italic> <xref ref-type="bibr" rid="pcbi.1003509-Shen1">[71]</xref> and Mazer <italic>et al</italic> <xref ref-type="bibr" rid="pcbi.1003509-Mazer1">[25]</xref>), we assume that FC is in rapid equilibrium between all of these species and that the amount of FC present on each particle surface (at equilibrium) is dependent only on the surface curvature, that is, the radius of the hydrophobic core of the particle (as represented in <xref ref-type="disp-formula" rid="pcbi.1003509.e134">equation (10)</xref>, below). The FC needed for the surface of the nascent spheres is assumed to be provided by the large pool of FC present in blood, including RBCs, and is largely replenished by the HDL remodeling processes. It can be shown that the rate at which FC is eliminated from plasma via holo-uptake of HDL particles is very small compared to the RCT rate (&lt;4%) and is therefore negligible from the perspective of mass balance. Similar considerations apply to the mass balance of PL.</p>
</sec><sec id="s3a2">
<title>Particle size</title>
<p>The size of spherical <italic>α</italic>-HDL particles is computed in the model as follows. From the pool size of CE in <italic>α</italic>-HDL and the particle concentration, the number of CE molecules per HDL particle is given by:<disp-formula id="pcbi.1003509.e120"><graphic position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1003509.e120" xlink:type="simple"/><label>(6)</label></disp-formula>Since <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e121" xlink:type="simple"/></inline-formula> is expressed as an equivalent mass of FC and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e122" xlink:type="simple"/></inline-formula> is the molecular weight of FC, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e123" xlink:type="simple"/></inline-formula> is appropriately determined. With an assumed ratio of TG/CE = 0.13 in the core of HDL particles <xref ref-type="bibr" rid="pcbi.1003509-Mazer1">[25]</xref>, we sum the volumes occupied by CE and TG to obtain the total core volume and determine the core radius (<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e124" xlink:type="simple"/></inline-formula>) from it. Finally, the surface thickness <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e125" xlink:type="simple"/></inline-formula> Å is added to the core radius, giving rise to following expression for the particle diameter, <italic>d</italic> (in Å):<disp-formula id="pcbi.1003509.e126"><graphic position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1003509.e126" xlink:type="simple"/><label>(7)</label></disp-formula><disp-formula id="pcbi.1003509.e127"><graphic position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1003509.e127" xlink:type="simple"/><label>(8)</label></disp-formula>Note that the molecular volumes <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e128" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e129" xlink:type="simple"/></inline-formula> are defined in <xref ref-type="table" rid="pcbi-1003509-t003">Table 3</xref>.</p>
</sec><sec id="s3a3">
<title>Remodeling flux</title>
<p>In the derivation of the remodeling flux, we compute the excess (or deficit) of ApoA-I compared to that derived using the updated Shen's model <xref ref-type="bibr" rid="pcbi.1003509-Mazer1">[25]</xref>. Given the pool size for <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e130" xlink:type="simple"/></inline-formula> and the particle concentration <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e131" xlink:type="simple"/></inline-formula>, we compute the number of ApoA-I molecules per particle:<disp-formula id="pcbi.1003509.e132"><graphic position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1003509.e132" xlink:type="simple"/><label>(9)</label></disp-formula>Using the expression for <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e133" xlink:type="simple"/></inline-formula> given in (7), the number of ApoA-I molecules needed to cover the surface is derived in the following manner <xref ref-type="bibr" rid="pcbi.1003509-Mazer1">[25]</xref>: firstly, the number of free cholesterol is computed,<disp-formula id="pcbi.1003509.e134"><graphic position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1003509.e134" xlink:type="simple"/><label>(10)</label></disp-formula>Then, the number of phospholipid molecules needed to cover the remaining surface area of the core is computed:<disp-formula id="pcbi.1003509.e135"><graphic position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1003509.e135" xlink:type="simple"/><label>(11)</label></disp-formula>where the cross-sectional surface areas of cholesterol and phospholipid are <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e136" xlink:type="simple"/></inline-formula> Å<sup>2</sup> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e137" xlink:type="simple"/></inline-formula> Å<sup>2</sup> respectively. The number of amino acids needed to cover the hydrophobic area exposed at the outer surface layer of HDL particle is:<disp-formula id="pcbi.1003509.e138"><graphic position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1003509.e138" xlink:type="simple"/><label>(12)</label></disp-formula>where the cross-sectional area of an amino acid <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e139" xlink:type="simple"/></inline-formula> Å<sup>2</sup>. Since there are 243 amino acids in ApoA-I, under the further assumption that the weight fraction of ApoA-I in the HDL proteome is 60% <xref ref-type="bibr" rid="pcbi.1003509-Mazer1">[25]</xref>, the number of ApoA-I molecules needed to cover the surface of HDL is given by:<disp-formula id="pcbi.1003509.e140"><graphic position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1003509.e140" xlink:type="simple"/><label>(13)</label></disp-formula>Finally, the discrepancy between the number of ApoA-I on the HDL (9) and the number needed from the Shen model (13), is the excess (or deficit) ApoA-I. Given the HDL particle concentration <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e141" xlink:type="simple"/></inline-formula>, the following is the concentration of ApoA-I on <italic>α</italic>-HDL which is available to dissociate as the remodeling flux:<disp-formula id="pcbi.1003509.e142"><graphic position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1003509.e142" xlink:type="simple"/><label>(14)</label></disp-formula></p>
</sec><sec id="s3a4">
<title>HDL holo-particle uptake</title>
<p>Our model allows for the possibility of a linear size dependence of the HDL holo-particle uptake rate. However, no prior assumption is made regarding the size dependency; using the calibration data, the sign and magnitude of the linear dependence is determined. In particular, the rate of holo-uptake has the following form, where the calculation of size <italic>d</italic> is given by <xref ref-type="disp-formula" rid="pcbi.1003509.e127">equation (8)</xref> and the division by 10 accounts for the conversion from Å to nm:<disp-formula id="pcbi.1003509.e143"><graphic position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1003509.e143" xlink:type="simple"/><label>(15)</label></disp-formula></p>
</sec></sec><sec id="s3b">
<title>Parameter priors</title>
<p>In this section, prior estimates of model parameters are given, including references to the original literature and the rationale for the choice of prior and the level of uncertainty. In a manner similar to a previously proposed Bayesian approach <xref ref-type="bibr" rid="pcbi.1003509-Jonsson1">[35]</xref>, uncertainty is increased by a factor <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e144" xlink:type="simple"/></inline-formula> in the following cases:</p>
<list list-type="bullet"><list-item>
<p>quantities that are measured <italic>in-vitro</italic> and mapped to the <italic>in-vivo</italic> context;</p>
</list-item><list-item>
<p>quantities that are measured in a population with mutation(s) and mapped to normal subjects;</p>
</list-item><list-item>
<p>quantities that result from pooling data obtained using distinct experimental techniques/assumptions.</p>
</list-item></list>
<p>No explicit prior correlations are assumed.</p>
<sec id="s3b1">
<title>Synthesis rate of ApoA-I (<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e145" xlink:type="simple"/></inline-formula>)</title>
<p>The kinetics of ApoA-I were measured in <italic>n</italic> = 20 (11 males, 9 females) healthy subjects, with mean HDL-C = 46 mg/dL and ApoA-I = 115 mg/dL <xref ref-type="bibr" rid="pcbi.1003509-Schaefer1">[44]</xref>. The ApoA-I synthesis rate has been estimated to be <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e146" xlink:type="simple"/></inline-formula> mg/dL/day (mean±SD). Hence, we take <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e147" xlink:type="simple"/></inline-formula> mg/dL/day (mean±SEM).</p>
</sec><sec id="s3b2">
<title>Rate of kidney elimination (<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e148" xlink:type="simple"/></inline-formula>)</title>
<p>There have been a number of papers describing the measurement of the FCR of pre-<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e149" xlink:type="simple"/></inline-formula> <xref ref-type="bibr" rid="pcbi.1003509-Chetiveaux1">[22]</xref>, <xref ref-type="bibr" rid="pcbi.1003509-Li1">[72]</xref>. However, the quantification of pre-<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e150" xlink:type="simple"/></inline-formula> can be a challenging task and a more direct assessment of the clearance rate of lipid-poor ApoA-I is estimated by the FCR of ApoA-I in Tangier patients. In the model representation of homozygous Tangier patients (<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e151" xlink:type="simple"/></inline-formula>, the FCR of ApoA-I equals the kidney clearance of lipid-poor ApoA-I. The hypothesis that kidneys is responsible for a large fraction of ApoA-I clearance is supported by the study of Braschi <italic>et al</italic> done using rabbits <xref ref-type="bibr" rid="pcbi.1003509-Braschi1">[73]</xref>, where it was estimated that the kidneys contribute around 70% of total ApoA-I clearance. The residence times (RT) of ApoA-I in Tangier disease patients have been measured to be <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e152" xlink:type="simple"/></inline-formula> day in <xref ref-type="bibr" rid="pcbi.1003509-Bojanovski1">[74]</xref> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e153" xlink:type="simple"/></inline-formula> day in <xref ref-type="bibr" rid="pcbi.1003509-Schaefer2">[75]</xref>. It is assumed that in Tangier patients, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e154" xlink:type="simple"/></inline-formula> = 1/RT. Thus, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e155" xlink:type="simple"/></inline-formula> has been estimated to be <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e156" xlink:type="simple"/></inline-formula> pool/day (mean±SEM). Because of the assumption made in mapping ApoA-I clearance measured in the Tangier patients to the normal population, we apply the factor <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e157" xlink:type="simple"/></inline-formula> to give <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e158" xlink:type="simple"/></inline-formula> pool/day (mean±SEM).</p>
</sec><sec id="s3b3">
<title>Dissociation rate constant of labile ApoA-I (<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e159" xlink:type="simple"/></inline-formula>)</title>
<p>In <xref ref-type="bibr" rid="pcbi.1003509-Cavigiolio1">[76]</xref>, fluorescence resonance energy transfer spectroscopy was used to quantify the rate of ApoA-I exchange. In this <italic>in-vitro</italic> set-up using synthetic rHDL incubated with 5-molar excess of lipid-free ApoA-I, the exponential relaxation time (defined as the time by which 50% of the exchange has occurred) was inferred to be 0.94 hour. This gives rise to the estimate of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e160" xlink:type="simple"/></inline-formula> pool/day <xref ref-type="bibr" rid="pcbi.1003509-Cavigiolio1">[76]</xref>. The ApoA-I found on <italic>α</italic>-HDL particles can be divided into a tightly-bound pool <xref ref-type="bibr" rid="pcbi.1003509-Cheung1">[77]</xref> and a labile pool <xref ref-type="bibr" rid="pcbi.1003509-LundKatz1">[78]</xref>. The study of the dissociation of ApoA-I molecules from the labile pool is carried out in <xref ref-type="bibr" rid="pcbi.1003509-LundKatz1">[78]</xref>, where surface plasmon resonance was used to study the kinetics of ApoA-I interaction with HDL particles. A two-state binding model was used to describe the association and dissociation reactions and the rate parameters were identified from the time-course data. It has been found that for the pool of ApoA-I molecules that are bound to HDL particles in a stable conformation, the half-time of dissociation is around 3 minutes, corresponding to <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e161" xlink:type="simple"/></inline-formula> pool/day. Computing the mean and SD of the two estimates of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e162" xlink:type="simple"/></inline-formula> and using <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e163" xlink:type="simple"/></inline-formula> to account for the fact that these values were measured <italic>in-vitro</italic>, we obtain <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e164" xlink:type="simple"/></inline-formula> pool/day (mean±SEM).</p>
</sec><sec id="s3b4">
<title>Rate constant of the lipidation of lipid-poor ApoA-I via ABCA1 (<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e165" xlink:type="simple"/></inline-formula>)</title>
<p>The model assumes that the lipidation of ApoA-I is initiated by ABCA1, leading to the formation of nascent discs and subsequently to nascent spheres (via LCAT). While LCAT is crucial for the esterification of free cholesterol to cholesteryl ester, ABCA1 activity is assumed to be rate-limiting in the formation of <italic>α</italic>-HDL. In the model, the rate at which the concatenation of processes leading from lipid-poor ApoA-I to mature, <italic>α</italic>-HDL is described by the ABCA1 activity, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e166" xlink:type="simple"/></inline-formula>. Based on the size exclusion chromatographic technique for separating HDL into subclasses, the rate constant in the conversion of lipid-poor ApoA-I to the <italic>α</italic>-HDL pool has been estimated to be <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e167" xlink:type="simple"/></inline-formula> pool/day (mean±SD, n = 6) <xref ref-type="bibr" rid="pcbi.1003509-Chetiveaux1">[22]</xref>. Thus, the mean and SEM is given by <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e168" xlink:type="simple"/></inline-formula> pool/day (mean±SEM).</p>
</sec><sec id="s3b5">
<title>Stoichiometry of FC to ApoA-I in nascent discs (<italic>γ</italic>)</title>
<p>In the model, <italic>γ</italic> denotes the stoichiometry (or molar ratio) of FC to ApoA-I in nascent discs. Due to the model assumption that FC in nascent discs are all esterified and result in the formation of nascent spheres, <italic>γ</italic> also equals the stoichiometry of CE to ApoA-I entering the <italic>α</italic>-HDL pool. Given these two interpretations of the model parameter <italic>γ</italic>, there are alternative ways to estimate it from literature data. In <xref ref-type="bibr" rid="pcbi.1003509-Castro1">[79]</xref>, plasma was fractionated using two-dimensional electrophoresis and the composition of pre-<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e169" xlink:type="simple"/></inline-formula> was analyzed. The weight fraction of FC to ApoA-I was found to be <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e170" xlink:type="simple"/></inline-formula> (n = 4). Using the given molecular weights of ApoA-I and FC, we obtain the molar ratio of FC/ApoA-I = <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e171" xlink:type="simple"/></inline-formula> (mean±SEM). An alternative estimate of <italic>γ</italic> is obtained using the estimates for the rate of cholesterol esterification to HDL-CE (<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e172" xlink:type="simple"/></inline-formula> mg/dL/day, <italic>n</italic> = 3) <xref ref-type="bibr" rid="pcbi.1003509-Ouguerram1">[20]</xref> as well as the production rate of <italic>α</italic>-HDL from pre-<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e173" xlink:type="simple"/></inline-formula> (<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e174" xlink:type="simple"/></inline-formula> mg/dL/day, <italic>n</italic> = 6) <xref ref-type="bibr" rid="pcbi.1003509-Chetiveaux1">[22]</xref>. Thus, using these sets of data <italic>γ</italic> is estimated to be <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e175" xlink:type="simple"/></inline-formula> (mean ± SEM). Finally, an <italic>in-vitro</italic> experiment has been carried out to characterize the composition of nascent HDL (nHDL) formed by the action of ABCA1 on ApoA-I <xref ref-type="bibr" rid="pcbi.1003509-SorciThomas1">[80]</xref>. For the small nHDL formed (diameter ≈7.5 nm), the particles were found to contain, on average, 2 ApoA-I and 9 total cholesterol. This gives the estimate for <italic>γ</italic> of 4.5. Thus, combining all three estimates we get <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e176" xlink:type="simple"/></inline-formula> (mean±SEM). Using the factor <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e177" xlink:type="simple"/></inline-formula> to take into account that <italic>in-vitro</italic> estimates were used, we obtain the final estimate of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e178" xlink:type="simple"/></inline-formula> (mean±SEM).</p>
</sec><sec id="s3b6">
<title>Rate constant of CE transfer from HDL to VLDL (<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e179" xlink:type="simple"/></inline-formula>)</title>
<p>In <xref ref-type="bibr" rid="pcbi.1003509-Ouguerram1">[20]</xref>, the unidirectional movement of CE from HDL to VLDL was quantified using a two -pool model for CE in the Apo B-100 particle classes (VLDL and LDL) and a single pool for CE in HDL particles. Using the data from <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e180" xlink:type="simple"/></inline-formula> subjects, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e181" xlink:type="simple"/></inline-formula> is estimated to be <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e182" xlink:type="simple"/></inline-formula> pool/day (mean±SD). The rate of CE movement from HDL particles to VLDL has also been quantified in <xref ref-type="bibr" rid="pcbi.1003509-Schwartz2">[21]</xref>. In this compartmental analysis, a 3-pool model has been used for CE in Apo-B particles (VLDL, IDL and LDL) and bidirectionality of transfer has been assumed between HDL and VLDL as well as between HDL and LDL. Due to the fact that our model does not account for IDL, the CE transfers for this density class are pooled into those of VLDL. For <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e183" xlink:type="simple"/></inline-formula> normal subjects, the net transfers of CE from HDL to VLDL and IDL are <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e184" xlink:type="simple"/></inline-formula> mg/dL/day. Normalizing by the individual concentrations of HDL-CE, this gives the estimate of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e185" xlink:type="simple"/></inline-formula> pool/day (mean±SD). By pooling the data sets from both Ouguerram <italic>et al</italic> <xref ref-type="bibr" rid="pcbi.1003509-Ouguerram1">[20]</xref> and Schwartz <italic>et al</italic> <xref ref-type="bibr" rid="pcbi.1003509-Schwartz2">[21]</xref> and using <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e186" xlink:type="simple"/></inline-formula> to account for the difference in the structures of compartmental models, we obtain: <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e187" xlink:type="simple"/></inline-formula> pool/day (mean±SEM).</p>
</sec><sec id="s3b7">
<title>Rate constant of CE transfer from HDL to LDL (<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e188" xlink:type="simple"/></inline-formula>)</title>
<p>In <xref ref-type="bibr" rid="pcbi.1003509-Ouguerram1">[20]</xref>, the movement of CE from HDL to LDL was quantified using a two -pool model for CE in the Apo B-100 particle classes (VLDL and LDL) and a single pool for CE in HDL particles. Using the data from the 3 subjects, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e189" xlink:type="simple"/></inline-formula> is estimated to be <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e190" xlink:type="simple"/></inline-formula> pool/day (mean±SD). A different estimate is obtained using the data for <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e191" xlink:type="simple"/></inline-formula> normal subjects given in <xref ref-type="bibr" rid="pcbi.1003509-Schwartz2">[21]</xref>: by dividing the rates of CE movement from HDL particles to LDL by the concentrations of HDL-CE at the individual level, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e192" xlink:type="simple"/></inline-formula> is estimated to be <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e193" xlink:type="simple"/></inline-formula> pool/day (mean±SD). By pooling the data sets from both Ouguerram <italic>et al</italic> <xref ref-type="bibr" rid="pcbi.1003509-Ouguerram1">[20]</xref> and Schwartz <italic>et al</italic> <xref ref-type="bibr" rid="pcbi.1003509-Schwartz2">[21]</xref> and using <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e194" xlink:type="simple"/></inline-formula> to account for the difference in the structures of compartmental models, we obtain: <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e195" xlink:type="simple"/></inline-formula> pool/day (mean±SEM).</p>
</sec><sec id="s3b8">
<title>Rate constant of CE transfer from LDL to HDL (<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e196" xlink:type="simple"/></inline-formula>)</title>
<p>In <xref ref-type="bibr" rid="pcbi.1003509-Ouguerram1">[20]</xref>, the rate of CE transfer from LDL to HDL was quantified using a two -pool model for CE in the Apo B-100 particle classes (VLDL and LDL) and a single pool for CE in HDL particles. Using the data from the 3 subjects, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e197" xlink:type="simple"/></inline-formula> is estimated to be <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e198" xlink:type="simple"/></inline-formula> pool/day (mean±SD). An alternative estimate is obtained using the data for <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e199" xlink:type="simple"/></inline-formula> normal subjects given in <xref ref-type="bibr" rid="pcbi.1003509-Schwartz2">[21]</xref>: by dividing the rates of CE movement from LDL particles to HDL by the concentrations of LDL-CE at the individual level, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e200" xlink:type="simple"/></inline-formula> is estimated to be <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e201" xlink:type="simple"/></inline-formula> pool/day (mean±SD). By pooling the data sets from both Ouguerram <italic>et al</italic> <xref ref-type="bibr" rid="pcbi.1003509-Ouguerram1">[20]</xref> and Schwartz <italic>et al</italic> <xref ref-type="bibr" rid="pcbi.1003509-Schwartz2">[21]</xref> and using <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e202" xlink:type="simple"/></inline-formula> to account for the difference in the structures of compartmental models, we obtain: <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e203" xlink:type="simple"/></inline-formula> pool/day (mean±SEM).</p>
</sec><sec id="s3b9">
<title>Rate constant of transfer of CE from VLDL to LDL (<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e204" xlink:type="simple"/></inline-formula>)</title>
<p>In <xref ref-type="bibr" rid="pcbi.1003509-Ouguerram1">[20]</xref>, the rate constant of CE transfer from VLDL to LDL (due primarily to lipolysis) was inferred in <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e205" xlink:type="simple"/></inline-formula> normal subjects: this gives rise to the parameter estimate <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e206" xlink:type="simple"/></inline-formula> pool/day (mean±SEM).</p>
</sec><sec id="s3b10">
<title>Flux of CE to VLDL (<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e207" xlink:type="simple"/></inline-formula>)</title>
<p>In <xref ref-type="bibr" rid="pcbi.1003509-Ouguerram1">[20]</xref>, the flux of CE into the VLDL pool was inferred in <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e208" xlink:type="simple"/></inline-formula> normal subjects to be <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e209" xlink:type="simple"/></inline-formula> mg/dL/day (mean±SD). The cholesteryl ester production to VLDL was also measured by Schwartz <italic>et al</italic> in <xref ref-type="bibr" rid="pcbi.1003509-Schwartz2">[21]</xref>, but due to the large uncertainty as represented by the greater than 100% SD in some of the individual data, these values have not been used. Thus, we take <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e210" xlink:type="simple"/></inline-formula> mg/dL/day (mean±SEM).</p>
</sec><sec id="s3b11">
<title>Rate constant of CE elimination from VLDL (<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e211" xlink:type="simple"/></inline-formula>)</title>
<p>In <xref ref-type="bibr" rid="pcbi.1003509-Ouguerram1">[20]</xref>, the rate constant of CE elimination from the VLDL pool was inferred in <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e212" xlink:type="simple"/></inline-formula> normal subjects to be <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e213" xlink:type="simple"/></inline-formula> pool/day (mean±SD). The quantification of CE elimination rate from VLDL was also carried out by Schwartz <italic>et al</italic> in <xref ref-type="bibr" rid="pcbi.1003509-Schwartz2">[21]</xref>, but the mean of the data was not shown in the paper because most values were undefined (fractional SD &gt;80%). Thus, we use only the values given by Ouguerram <italic>et al</italic> <xref ref-type="bibr" rid="pcbi.1003509-Ouguerram1">[20]</xref> and take <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e214" xlink:type="simple"/></inline-formula> pool/day (mean±SEM).</p>
</sec><sec id="s3b12">
<title>Rate constant of CE elimination from LDL (<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e215" xlink:type="simple"/></inline-formula>)</title>
<p>In <xref ref-type="bibr" rid="pcbi.1003509-Ouguerram1">[20]</xref>, the rate constant of CE elimination from the LDL pool was inferred in <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e216" xlink:type="simple"/></inline-formula> normal subjects to be <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e217" xlink:type="simple"/></inline-formula> pool/day (mean±SD). The quantification of CE elimination rate from LDL was also carried out by Schwartz <italic>et al</italic> in <xref ref-type="bibr" rid="pcbi.1003509-Schwartz2">[21]</xref>, but the mean of the flux to the extra-hepatic pool was not shown in the paper because most values were undefined (fractional SD &gt;80%). Thus, we use only the value given by Ouguerram <italic>et al</italic> <xref ref-type="bibr" rid="pcbi.1003509-Ouguerram1">[20]</xref> and take <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e218" xlink:type="simple"/></inline-formula> pool/day (mean±SEM).</p>
</sec><sec id="s3b13">
<title>Rate constant of SRB1-mediated CE elimination from HDL (<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e219" xlink:type="simple"/></inline-formula>)</title>
<p>In <xref ref-type="bibr" rid="pcbi.1003509-Ouguerram1">[20]</xref>, the rate constant of selective CE elimination from the HDL pool was inferred in <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e220" xlink:type="simple"/></inline-formula> normal subjects to be <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e221" xlink:type="simple"/></inline-formula> pool/day (mean±SD). The selective uptake of HDL-CE by the liver was not observed in Schwartz <italic>et al</italic> in <xref ref-type="bibr" rid="pcbi.1003509-Schwartz2">[21]</xref>. Hence, we use only the value given by Ouguerram <italic>et al</italic> <xref ref-type="bibr" rid="pcbi.1003509-Ouguerram1">[20]</xref> and take <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e222" xlink:type="simple"/></inline-formula> pool/day <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e223" xlink:type="simple"/></inline-formula>.</p>
</sec><sec id="s3b14">
<title>Rate constant of size-independent holo-particle uptake for <italic>α</italic>-HDL (<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e224" xlink:type="simple"/></inline-formula>)</title>
<p>The FCR of ApoA-I in the <italic>α</italic>-HDL pool has been estimated to be <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e225" xlink:type="simple"/></inline-formula> pool/day (mean±SD, n = 6) using HDL subclasses separated with size exclusion chromatography <xref ref-type="bibr" rid="pcbi.1003509-Chetiveaux1">[22]</xref>. In another reference <xref ref-type="bibr" rid="pcbi.1003509-Li1">[72]</xref>, using a separation technique based on agarose gel electrophoresis, the FCR of ApoA-I in the <italic>α</italic>-HDL pool has been estimated to be <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e226" xlink:type="simple"/></inline-formula> pool/day (mean±SD, <italic>n</italic> = 6). Thus, by pooling the data we obtain <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e227" xlink:type="simple"/></inline-formula> pool/day (mean±SEM). Finally, using the factor <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e228" xlink:type="simple"/></inline-formula>, we get <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e229" xlink:type="simple"/></inline-formula> pool/day (mean±SEM).</p>
</sec></sec><sec id="s3c">
<title>Calibration data</title>
<p>In this section, we give the quantitative values and references for the data used in the calibration procedure.</p>
<sec id="s3c1">
<title>CETP mutation</title>
<p>Lipoprotein data for CETP mutation patients were taken from 3 sources: Inazu <italic>et al</italic> <xref ref-type="bibr" rid="pcbi.1003509-Inazu1">[81]</xref>, Yamashita <italic>et al</italic> <xref ref-type="bibr" rid="pcbi.1003509-Yamashita1">[82]</xref> and Asztalos <italic>et al</italic> <xref ref-type="bibr" rid="pcbi.1003509-Asztalos4">[83]</xref> and were pooled to yield the mean and SEM. In particular, both HDL-C and ApoA-I were available for each of the 3 data sources shown in <xref ref-type="table" rid="pcbi-1003509-t006">Table 6</xref>. The values for LDL-CE and VLDL-CE for the control subjects were not given in the references for CETP mutation <xref ref-type="bibr" rid="pcbi.1003509-Inazu1">[81]</xref>–<xref ref-type="bibr" rid="pcbi.1003509-Asztalos4">[83]</xref>; hence, the values from Ouguerram <italic>et al</italic> <xref ref-type="bibr" rid="pcbi.1003509-Ouguerram1">[20]</xref> and Schwartz <italic>et al</italic> <xref ref-type="bibr" rid="pcbi.1003509-Schwartz2">[21]</xref> were used in <xref ref-type="table" rid="pcbi-1003509-t007">Table 7</xref>. The value of LDL-CE for CETP heterozygotes was also used for calibrating the model, which was estimated using the given value of LDL-C with an assumption on the ratio of FC/CE for LDL particles. In Asztalos <italic>et al</italic> <xref ref-type="bibr" rid="pcbi.1003509-Asztalos4">[83]</xref>, the ratio of FC/CE for all lipoprotein particle classes of CETP heterozygotes was given as 0.37, which gives CE = 0.73×TC. Given the approximations made, we assumed that LDL-CE = LDL-C <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e230" xlink:type="simple"/></inline-formula>. There is literature data for LDL-CE and/or VLDL-CE in CETP homozygotes <xref ref-type="bibr" rid="pcbi.1003509-Ritsch1">[39]</xref>–<xref ref-type="bibr" rid="pcbi.1003509-Teh1">[41]</xref>, but these were not used in the calibration process due to the known inconsistency of the model in lacking the <italic>β</italic>-LCAT activity <xref ref-type="bibr" rid="pcbi.1003509-Carlson1">[42]</xref>.</p>
<table-wrap id="pcbi-1003509-t006" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1003509.t006</object-id><label>Table 6</label><caption>
<title>Calibration data: HDL-C and ApoA-I in normal and CETP deficient subjects.</title>
</caption><alternatives><graphic id="pcbi-1003509-t006-6" position="float" mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1003509.t006" xlink:type="simple"/>
<table><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup>
<thead>
<tr>
<td align="left" rowspan="1" colspan="1">Type</td>
<td align="left" rowspan="1" colspan="1">Data</td>
<td align="left" rowspan="1" colspan="1">Inazu <xref ref-type="bibr" rid="pcbi.1003509-Inazu1">[81]</xref> (mean±SD)</td>
<td align="left" rowspan="1" colspan="1">Yamashita <xref ref-type="bibr" rid="pcbi.1003509-Yamashita1">[82]</xref> (mean±SD)</td>
<td align="left" rowspan="1" colspan="1">Asztalos <xref ref-type="bibr" rid="pcbi.1003509-Asztalos4">[83]</xref> (mean±SD)</td>
<td align="left" rowspan="1" colspan="1">Pooled (mean±SEM)</td>
</tr>
</thead>
<tbody>
<tr>
<td align="left" rowspan="1" colspan="1">Normal Subjects</td>
<td align="left" rowspan="1" colspan="1"><italic>n</italic></td>
<td align="left" rowspan="1" colspan="1">16</td>
<td align="left" rowspan="1" colspan="1">20</td>
<td align="left" rowspan="1" colspan="1">50</td>
<td align="left" rowspan="1" colspan="1">86</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">HDL-C</td>
<td align="left" rowspan="1" colspan="1">52.9±13.9</td>
<td align="left" rowspan="1" colspan="1">50±8</td>
<td align="left" rowspan="1" colspan="1">52±14</td>
<td align="left" rowspan="1" colspan="1">52±1</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">ApoA-I</td>
<td align="left" rowspan="1" colspan="1">124±21</td>
<td align="left" rowspan="1" colspan="1">140.9±16.1</td>
<td align="left" rowspan="1" colspan="1">144±29</td>
<td align="left" rowspan="1" colspan="1">139±4</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Heterozygotes of CETP deficiency</td>
<td align="left" rowspan="1" colspan="1"><italic>n</italic></td>
<td align="left" rowspan="1" colspan="1">20</td>
<td align="left" rowspan="1" colspan="1">15</td>
<td align="left" rowspan="1" colspan="1">5</td>
<td align="left" rowspan="1" colspan="1">40</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">HDL-C</td>
<td align="left" rowspan="1" colspan="1">66±15</td>
<td align="left" rowspan="1" colspan="1">84±25</td>
<td align="left" rowspan="1" colspan="1">85±26</td>
<td align="left" rowspan="1" colspan="1">75±4</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">ApoA-I</td>
<td align="left" rowspan="1" colspan="1">149±43</td>
<td align="left" rowspan="1" colspan="1">155.3±22.1</td>
<td align="left" rowspan="1" colspan="1">154±25</td>
<td align="left" rowspan="1" colspan="1">152±5</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Homozygotes of CETP deficiency</td>
<td align="left" rowspan="1" colspan="1"><italic>n</italic></td>
<td align="left" rowspan="1" colspan="1">10</td>
<td align="left" rowspan="1" colspan="1">4</td>
<td align="left" rowspan="1" colspan="1">9</td>
<td align="left" rowspan="1" colspan="1">23</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">HDL-C</td>
<td align="left" rowspan="1" colspan="1">163.7±39</td>
<td align="left" rowspan="1" colspan="1">193±28</td>
<td align="left" rowspan="1" colspan="1">157±29</td>
<td align="left" rowspan="1" colspan="1">166±7</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">ApoA-I</td>
<td align="left" rowspan="1" colspan="1">213±47</td>
<td align="left" rowspan="1" colspan="1">233.5±22.3</td>
<td align="left" rowspan="1" colspan="1">252±25</td>
<td align="left" rowspan="1" colspan="1">232±8</td>
</tr>
</tbody>
</table>
</alternatives><table-wrap-foot><fn id="nt103"><label/><p>All concentrations are given in mg/dL.</p></fn></table-wrap-foot></table-wrap><table-wrap id="pcbi-1003509-t007" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1003509.t007</object-id><label>Table 7</label><caption>
<title>Calibration data: CE in ApoB particles.</title>
</caption><alternatives><graphic id="pcbi-1003509-t007-7" position="float" mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1003509.t007" xlink:type="simple"/>
<table><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup>
<thead>
<tr>
<td align="left" rowspan="1" colspan="1">Type</td>
<td align="left" rowspan="1" colspan="1">Data <xref ref-type="bibr" rid="pcbi.1003509-Ouguerram1">[20]</xref>, <xref ref-type="bibr" rid="pcbi.1003509-Schwartz2">[21]</xref></td>
<td align="left" rowspan="1" colspan="1">Pooled (mean±SEM)</td>
</tr>
</thead>
<tbody>
<tr>
<td align="left" rowspan="1" colspan="1">Normal subjects</td>
<td align="left" rowspan="1" colspan="1"><italic>n</italic></td>
<td align="left" rowspan="1" colspan="1">10</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">LDL-CE</td>
<td align="left" rowspan="1" colspan="1">83±3 mg/dL</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">VLDL-CE</td>
<td align="left" rowspan="1" colspan="1">5±1 mg/dL</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Heterozygotes of CETP deficiency</td>
<td align="left" rowspan="1" colspan="1"><italic>n</italic></td>
<td align="left" rowspan="1" colspan="1">23</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">LDL-CE (LDL-C ×0.7)</td>
<td align="left" rowspan="1" colspan="1">72±9 mg/dL</td>
</tr>
</tbody>
</table>
</alternatives></table-wrap></sec><sec id="s3c2">
<title>Cholesteryl ester flux</title>
<p>There are 2 literature data sources on the <italic>in-vivo</italic> flux of CE between HDL and ApoB-containing particles: Ouguerram <italic>et al</italic> <xref ref-type="bibr" rid="pcbi.1003509-Ouguerram1">[20]</xref> and Schwartz <italic>et al</italic> <xref ref-type="bibr" rid="pcbi.1003509-Schwartz2">[21]</xref>. While both data sets have been used in estimating the prior distribution of parameters involved in the exchanges of CE (see <xref ref-type="sec" rid="s3">Methods</xref> section), for the purpose of model calibration a choice between the 2 disparate data needed to be made. Given that the model structure in the description of CE exchanges between HDL, LDL and VLDL is based on that of Ouguerram <italic>et al</italic> <xref ref-type="bibr" rid="pcbi.1003509-Ouguerram1">[20]</xref>, it was decided that the same calibration data should be taken for the CE fluxes. The values used are shown in <xref ref-type="table" rid="pcbi-1003509-t008">Table 8</xref>.</p>
<table-wrap id="pcbi-1003509-t008" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1003509.t008</object-id><label>Table 8</label><caption>
<title>Calibration data: CE fluxes.</title>
</caption><alternatives><graphic id="pcbi-1003509-t008-8" position="float" mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1003509.t008" xlink:type="simple"/>
<table><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/></colgroup>
<thead>
<tr>
<td align="left" rowspan="1" colspan="1">CE flux (mean±SEM)</td>
<td align="left" rowspan="1" colspan="1">Data (mg/dL/day)</td>
</tr>
</thead>
<tbody>
<tr>
<td align="left" rowspan="1" colspan="1">HDL to VLDL</td>
<td align="left" rowspan="1" colspan="1">64±2</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">HDL to LDL</td>
<td align="left" rowspan="1" colspan="1">268±51</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">LDL to HDL</td>
<td align="left" rowspan="1" colspan="1">266±52</td>
</tr>
</tbody>
</table>
</alternatives></table-wrap></sec><sec id="s3c3">
<title>Fractional catabolic rate of apoA-I</title>
<p>Brinton <italic>et al</italic> have shown that a strong association exists between the fractional catabolic rate (FCR) of ApoA-I and the estimated HDL size, using a surrogate marker <xref ref-type="bibr" rid="pcbi.1003509-Brinton1">[43]</xref> (Brinton <italic>et al</italic> used HDL-C/(ApoA-I+ApoA-II), we re-analyzed their data taking HDL-C/ApoA-I as the surrogate marker). Their work has demonstrated that as much as 70% of the variability in the FCR of ApoA-I may be attributed to variations in HDL size, as estimated using <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e231" xlink:type="simple"/></inline-formula> <xref ref-type="bibr" rid="pcbi.1003509-Brinton1">[43]</xref>. This finding is corroborated with the individual data of ApoA-I metabolism from Schaefer <italic>et al</italic> <xref ref-type="bibr" rid="pcbi.1003509-Schaefer1">[44]</xref> measured in healthy volunteers. Finally, FCR of ApoA-I was also studied by Ikewaki <italic>et al</italic> <xref ref-type="bibr" rid="pcbi.1003509-Ikewaki2">[45]</xref> in comparing CETP mutation subjects with controls. All these data consistently show that the ApoA-I FCR exhibits an inverse relationship with the surrogate measure of HDL size. However, the trend does not continue indefinitely: even for CETP homozygous subjects with very large particles, ApoA-I FCR appears to reach a minimum of 0.135 pool/day. Hence, we have tried to describe the data in the simplest way, assuming a linear relationship between ApoA-I FCR and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e232" xlink:type="simple"/></inline-formula>, with a lower bound of 0.135. Using this linear assumption, the fit and confidence interval was computed and shown in <xref ref-type="fig" rid="pcbi-1003509-g004">Figure 4</xref>. The piecewise linear fit to the combined data is given by <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e233" xlink:type="simple"/></inline-formula>; the mean confidence interval corresponding to 1 SD in the line fit is approximately ±0.065 pool/day.</p>
</sec></sec><sec id="s3d">
<title>Model calibration</title>
<p>In this work, we assume that both the parameter prior and the data error are normally distributed. We employ the methodology of <italic>maximum a posteriori</italic> (MAP) <xref ref-type="bibr" rid="pcbi.1003509-Aster1">[31]</xref> to combine the prior information with calibration data. Due to the conjugacy property <xref ref-type="bibr" rid="pcbi.1003509-Aster1">[31]</xref> of the distributions, the posterior also has a normal distribution and the MAP solution is obtained by solving a nonlinear least squares problem. In our model, most of the parameters have an informative prior. For the set of parameters for which an informative prior is available, let <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e234" xlink:type="simple"/></inline-formula> denote the expected value of the prior distribution; otherwise, set <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e235" xlink:type="simple"/></inline-formula> to represent the lack of information. We take the covariance matrix for the prior distribution <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e236" xlink:type="simple"/></inline-formula> to have a diagonal structure: for parameters <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e237" xlink:type="simple"/></inline-formula> that have an informative prior, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e238" xlink:type="simple"/></inline-formula> is the variance of the prior distribution; for parameters that have an uninformative prior, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e239" xlink:type="simple"/></inline-formula>. That is, the prior distribution is assumed to be of the form <xref ref-type="bibr" rid="pcbi.1003509-Eydgahi1">[33]</xref>:<disp-formula id="pcbi.1003509.e240"><graphic position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1003509.e240" xlink:type="simple"/><label>(16)</label></disp-formula>Let <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e241" xlink:type="simple"/></inline-formula> denote the vector of calibration data and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e242" xlink:type="simple"/></inline-formula> the nonlinear mapping from model parameters to the observation, representing the model simulation of the data. Let <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e243" xlink:type="simple"/></inline-formula> denote the covariance matrix for the data. Hence, the conditional distribution of the data given the model parameter <italic>k</italic> is <xref ref-type="bibr" rid="pcbi.1003509-Eydgahi1">[33]</xref>:<disp-formula id="pcbi.1003509.e244"><graphic position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1003509.e244" xlink:type="simple"/><label>(17)</label></disp-formula>Thus, the posterior distribution <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e245" xlink:type="simple"/></inline-formula> for the model parameters is given by<disp-formula id="pcbi.1003509.e246"><graphic position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1003509.e246" xlink:type="simple"/><label>(18)</label></disp-formula>To find the MAP solution, the following nonlinear least squares problem is solved: with the objective function defined as,<disp-formula id="pcbi.1003509.e247"><graphic position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1003509.e247" xlink:type="simple"/><label>(19)</label></disp-formula>the MAP solution is the minimizer:<disp-formula id="pcbi.1003509.e248"><graphic position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1003509.e248" xlink:type="simple"/><label>(20)</label></disp-formula>Using parameter priors as given in <xref ref-type="table" rid="pcbi-1003509-t005">Table 5</xref> and calibration data as described in the previous section, the nonlinear least-squares problem was solved using genetic algorithm ga from the Matlab® Global Optimization Toolbox of MathWorks (<ext-link ext-link-type="uri" xlink:href="http://www.mathworks.com/" xlink:type="simple">http://www.mathworks.com/</ext-link>) to obtain <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e249" xlink:type="simple"/></inline-formula>. In particular, the hybrid option was selected: 100 generations of the genetic algorithm was run with a PopulationSize = 500, followed by constrained minimization (fmincon) using the setting MaxFunEvals = 10000, MaxIter = 1000. In all numerical integration of ODEs, the relative and absolute tolerances were set to 10<sup>−9</sup>.</p>
</sec><sec id="s3e">
<title>Estimation of 95% confidence intervals</title>
<p>The confidence interval is estimated using the following procedure: parameters are sampled around <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e250" xlink:type="simple"/></inline-formula> and for each parameter the <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e251" xlink:type="simple"/></inline-formula> (with respect to its minimum, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e252" xlink:type="simple"/></inline-formula>) is computed according to the expression (19). An estimate of the confidence region is obtained by examining the set of all parameters that lie within <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e253" xlink:type="simple"/></inline-formula>, where <italic>δ</italic> is computed from the number of degrees of freedom (df) and the desired confidence level <xref ref-type="bibr" rid="pcbi.1003509-Press1">[84]</xref>. Using df = 29 for the model and choosing the 95% confidence level, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e254" xlink:type="simple"/></inline-formula>. A set of 1000 parameters satisfying <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003509.e255" xlink:type="simple"/></inline-formula> are selected in estimating confidence intervals shown in the paper.</p>
</sec><sec id="s3f">
<title>Simulation of tracer kinetic studies</title>
<p>The model simulations of the tracer kinetic experiment with labelled ApoA-I and the calculation of the FCR of ApoA-I were carried out using the technique of complex variable differentiation <xref ref-type="bibr" rid="pcbi.1003509-Martins1">[85]</xref>. In particular, a small quantity of imaginary number representing the radio-labelled dose of ApoA-I is added to the lipid-poor pool at the start of tracer experiment and the imaginary component of the numerical solution is extracted to represent the dose remaining in the two pools of ApoA-I (lipid-poor and <italic>α</italic>-HDL). This method relies on the complex extension of analytic functions from the real line, which can be easily implemented on the Matlab platform <xref ref-type="bibr" rid="pcbi.1003509-Martins1">[85]</xref>. As compared to the finite-differencing approach, the complex variable methodology does not suffer from subtractive cancellation error and hence is more accurate <xref ref-type="bibr" rid="pcbi.1003509-Martins1">[85]</xref>. While this approach has not been applied to tracer kinetic simulations, it has been applied to the sensitivity analysis of biological models <xref ref-type="bibr" rid="pcbi.1003509-Apgar1">[86]</xref>, <xref ref-type="bibr" rid="pcbi.1003509-Wei1">[87]</xref>.</p>
</sec></sec><sec id="s4">
<title>Supporting Information</title>
<supplementary-material id="pcbi.1003509.s001" mimetype="application/zip" xlink:href="info:doi/10.1371/journal.pcbi.1003509.s001" position="float" xlink:type="simple"><label>File S1</label><caption>
<p><bold>LMK model implementation in SimBiology and Matlab formats.</bold></p>
<p>(ZIP)</p>
</caption></supplementary-material></sec></body>
<back>
<ack>
<p>We would like to thank Daniel Serafin for his contribution in digitizing ApoA-I tracer kinetics data from <xref ref-type="fig" rid="pcbi-1003509-g003">Figure 3</xref> of Ikewaki <italic>et al</italic>, JLR 1993 and acknowledge anonymous reviewers whose detailed critique of the original manuscript helped to strengthen the final version. This paper is dedicated to the memory of Philippe Vuilleumier, a long time member of the MIT Club of Switzerland.</p>
</ack>
<ref-list>
<title>References</title>
<ref id="pcbi.1003509-DiAngelantonio1"><label>1</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Di Angelantonio</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Sarwar</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Perry</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Kaptoge</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Ray</surname><given-names>KK</given-names></name>, <etal>et al</etal>. (<year>2009</year>) <article-title>Major lipids, apolipoproteins, and risk of vascular disease</article-title>. <source>JAMA</source> <volume>302</volume>: <fpage>1993</fpage>–<lpage>2000</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003509-Larach1"><label>2</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Larach</surname><given-names>DB</given-names></name>, <name name-style="western"><surname>deGoma</surname><given-names>EM</given-names></name>, <name name-style="western"><surname>Rader</surname><given-names>DJ</given-names></name> (<year>2012</year>) <article-title>Targeting high density lipoproteins in the prevention of cardiovascular disease?</article-title> <source>Curr Cardiol Rep</source> <volume>14</volume>: <fpage>684</fpage>–<lpage>691</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003509-Hersberger1"><label>3</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hersberger</surname><given-names>M</given-names></name>, <name name-style="western"><surname>von Eckardstein</surname><given-names>A</given-names></name> (<year>2005</year>) <article-title>Modulation of high-density lipoprotein cholesterol metabolism and reverse cholesterol transport</article-title>. <source>Handb Exp Pharmacol</source> <volume>170</volume>: <fpage>537</fpage>–<lpage>561</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003509-Rothblat1"><label>4</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Rothblat</surname><given-names>GH</given-names></name>, <name name-style="western"><surname>Phillips</surname><given-names>MC</given-names></name> (<year>2010</year>) <article-title>High-density lipoprotein heterogeneity and function in reverse cholesterol transport</article-title>. <source>Curr Opin Lipidol</source> <volume>21</volume>: <fpage>229</fpage>–<lpage>238</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003509-Barter1"><label>5</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Barter</surname><given-names>PJ</given-names></name>, <name name-style="western"><surname>Caulfield</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Eriksson</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Grundy</surname><given-names>SM</given-names></name>, <name name-style="western"><surname>Kastelein</surname><given-names>JJ</given-names></name>, <etal>et al</etal>. (<year>2007</year>) <article-title>Effects of torcetrapib in patients at high risk for coronary events</article-title>. <source>N Engl J Med</source> <volume>357</volume>: <fpage>2109</fpage>–<lpage>2122</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003509-Boden1"><label>6</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Boden</surname><given-names>WE</given-names></name>, <name name-style="western"><surname>Probstfield</surname><given-names>JL</given-names></name>, <name name-style="western"><surname>Anderson</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Chaitman</surname><given-names>BR</given-names></name>, <name name-style="western"><surname>Desvignes-Nickens</surname><given-names>P</given-names></name>, <etal>et al</etal>. (<year>2011</year>) <article-title>Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy</article-title>. <source>N Engl J Med</source> <volume>365</volume>: <fpage>2255</fpage>–<lpage>2267</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003509-Schwartz1"><label>7</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Schwartz</surname><given-names>GG</given-names></name>, <name name-style="western"><surname>Olsson</surname><given-names>AG</given-names></name>, <name name-style="western"><surname>Abt</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Ballantyne</surname><given-names>CM</given-names></name>, <name name-style="western"><surname>Barter</surname><given-names>PJ</given-names></name>, <etal>et al</etal>. (<year>2012</year>) <article-title>Effects of dalcetrapib in patients with a recent acute coronary syndrome</article-title>. <source>N Engl J Med</source> <volume>367</volume>: <fpage>2089</fpage>–<lpage>2099</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003509-Rosenson1"><label>8</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Rosenson</surname><given-names>RS</given-names></name>, <name name-style="western"><surname>Brewer</surname><given-names>HB</given-names></name>, <name name-style="western"><surname>Davidson</surname><given-names>WS</given-names></name>, <name name-style="western"><surname>Fayad</surname><given-names>ZA</given-names></name>, <name name-style="western"><surname>Fuster</surname><given-names>V</given-names></name>, <etal>et al</etal>. (<year>2012</year>) <article-title>Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport</article-title>. <source>Circulation</source> <volume>125</volume>: <fpage>1905</fpage>–<lpage>1919</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003509-Rader1"><label>9</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Rader</surname><given-names>DJ</given-names></name>, <name name-style="western"><surname>Tall</surname><given-names>AR</given-names></name> (<year>2012</year>) <article-title>The not-so-simple HDL story: Is it time to revise the HDL cholesterol hypothesis?</article-title> <source>Nat Med</source> <volume>18</volume>: <fpage>1344</fpage>–<lpage>1346</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003509-Heinecke1"><label>10</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Heinecke</surname><given-names>JW</given-names></name> (<year>2012</year>) <article-title>The not-so-simple HDL story: A new era for quantifying HDL and cardiovascular risk?</article-title> <source>Nat Med</source> <volume>18</volume>: <fpage>1346</fpage>–<lpage>1347</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003509-deGraaf1"><label>11</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>de Graaf</surname><given-names>AA</given-names></name>, <name name-style="western"><surname>van Schalkwijk</surname><given-names>DB</given-names></name> (<year>2011</year>) <article-title>Computational models for analyzing lipoprotein profiles</article-title>. <source>Clinical Lipidology</source> <volume>6</volume>: <fpage>25</fpage>–<lpage>33</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003509-Lu1"><label>12</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lu</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Mazer</surname><given-names>NA</given-names></name>, <name name-style="western"><surname>Hübner</surname><given-names>K</given-names></name> (<year>2013</year>) <article-title>Mathematical models of lipoprotein metabolism and kinetics -current status and future perspectives</article-title>. <source>Clinical Lipidology</source> <volume>8</volume>: <fpage>595</fpage>–<lpage>604</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003509-Potter1"><label>13</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Potter</surname><given-names>LK</given-names></name>, <name name-style="western"><surname>Sprecher</surname><given-names>DL</given-names></name>, <name name-style="western"><surname>Walker</surname><given-names>MC</given-names></name>, <name name-style="western"><surname>Tobin</surname><given-names>FL</given-names></name> (<year>2009</year>) <article-title>Mechanism of inhibition defines CETP activity: a mathematical model for CETP in vitro</article-title>. <source>J Lipid Res</source> <volume>50</volume>: <fpage>2222</fpage>–<lpage>2234</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003509-vanSchalkwijk1"><label>14</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>van Schalkwijk</surname><given-names>DB</given-names></name>, <name name-style="western"><surname>de Graaf</surname><given-names>AA</given-names></name>, <name name-style="western"><surname>van Ommen</surname><given-names>B</given-names></name>, <name name-style="western"><surname>van Bochove</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Rensen</surname><given-names>PC</given-names></name>, <etal>et al</etal>. (<year>2009</year>) <article-title>Improved cholesterol phenotype analysis by a model relating lipoprotein life cycle processes to particle size</article-title>. <source>J Lipid Res</source> <volume>50</volume>: <fpage>2398</fpage>–<lpage>2411</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003509-Knoblauch1"><label>15</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Knoblauch</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Schuster</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Luft</surname><given-names>FC</given-names></name>, <name name-style="western"><surname>Reich</surname><given-names>J</given-names></name> (<year>2000</year>) <article-title>A pathway model of lipid metabolism to predict the effect of genetic variability on lipid levels</article-title>. <source>J Mol Med</source> <volume>78</volume>: <fpage>507</fpage>–<lpage>515</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003509-Hbner1"><label>16</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hübner</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Schwager</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Winkler</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Reich</surname><given-names>JG</given-names></name>, <name name-style="western"><surname>Holzhütter</surname><given-names>HG</given-names></name> (<year>2008</year>) <article-title>Computational lipidology: predicting lipoprotein density profiles in human blood plasma</article-title>. <source>PLoS Comput Biol</source> <volume>4</volume>: <fpage>e1000079</fpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003509-vandePas1"><label>17</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>van de Pas</surname><given-names>NC</given-names></name>, <name name-style="western"><surname>Woutersen</surname><given-names>RA</given-names></name>, <name name-style="western"><surname>van Ommen</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Rietjens</surname><given-names>IM</given-names></name>, <name name-style="western"><surname>de Graaf</surname><given-names>AA</given-names></name> (<year>2012</year>) <article-title>A physiologically based in silico kinetic model predicting plasma cholesterol concentrations in humans</article-title>. <source>J Lipid Res</source> <volume>53</volume>: <fpage>2734</fpage>–<lpage>2746</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003509-McAuley1"><label>18</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Mc Auley</surname><given-names>MT</given-names></name>, <name name-style="western"><surname>Wilkinson</surname><given-names>DJ</given-names></name>, <name name-style="western"><surname>Jones</surname><given-names>JJ</given-names></name>, <name name-style="western"><surname>Kirkwood</surname><given-names>TB</given-names></name> (<year>2012</year>) <article-title>A whole-body mathematical model of cholesterol metabolism and its age-associated dysregulation</article-title>. <source>BMC Syst Biol</source> <volume>6</volume>: <fpage>130</fpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003509-Tiemann1"><label>19</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Tiemann</surname><given-names>CA</given-names></name>, <name name-style="western"><surname>Vanlier</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Oosterveer</surname><given-names>MH</given-names></name>, <name name-style="western"><surname>Groen</surname><given-names>AK</given-names></name>, <name name-style="western"><surname>Hilbers</surname><given-names>PA</given-names></name>, <etal>et al</etal>. (<year>2013</year>) <article-title>Parameter trajectory analysis to identify treatment effects of pharmacological interventions</article-title>. <source>PLoS Comput Biol</source> <volume>9</volume>: <fpage>e1003166</fpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003509-Ouguerram1"><label>20</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ouguerram</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Krempf</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Maugeais</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Maugere</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Darmaun</surname><given-names>D</given-names></name>, <etal>et al</etal>. (<year>2002</year>) <article-title>A new labeling approach using stable isotopes to study in vivo plasma cholesterol metabolism in humans</article-title>. <source>Metab Clin Exp</source> <volume>51</volume>: <fpage>5</fpage>–<lpage>11</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003509-Schwartz2"><label>21</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Schwartz</surname><given-names>CC</given-names></name>, <name name-style="western"><surname>VandenBroek</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Cooper</surname><given-names>PS</given-names></name> (<year>2004</year>) <article-title>Lipoprotein cholesteryl ester production, transfer, and output in vivo in humans</article-title>. <source>J Lipid Res</source> <volume>45</volume>: <fpage>1594</fpage>–<lpage>1607</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003509-Chetiveaux1"><label>22</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Chetiveaux</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Ouguerram</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Zair</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Maugere</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Falconi</surname><given-names>I</given-names></name>, <etal>et al</etal>. (<year>2004</year>) <article-title>New model for kinetic studies of HDL metabolism in humans</article-title>. <source>Eur J Clin Invest</source> <volume>34</volume>: <fpage>262</fpage>–<lpage>267</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003509-Rye1"><label>23</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Rye</surname><given-names>KA</given-names></name>, <name name-style="western"><surname>Clay</surname><given-names>MA</given-names></name>, <name name-style="western"><surname>Barter</surname><given-names>PJ</given-names></name> (<year>1999</year>) <article-title>Remodelling of high density lipoproteins by plasma factors</article-title>. <source>Atherosclerosis</source> <volume>145</volume>: <fpage>227</fpage>–<lpage>238</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003509-Adiels1"><label>24</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Adiels</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Packard</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Caslake</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>Stewart</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Soro</surname><given-names>A</given-names></name>, <etal>et al</etal>. (<year>2005</year>) <article-title>A new combined multicompartmental model for apolipoprotein B-100 and triglyceride metabolism in VLDL subfractions</article-title>. <source>J Lipid Res</source> <volume>46</volume>: <fpage>58</fpage>–<lpage>67</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003509-Mazer1"><label>25</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Mazer</surname><given-names>NA</given-names></name>, <name name-style="western"><surname>Giulianini</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Paynter</surname><given-names>NP</given-names></name>, <name name-style="western"><surname>Jordan</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Mora</surname><given-names>S</given-names></name> (<year>2013</year>) <article-title>A comparison of the theoretical relationship between HDL size and the ratio of HDL cholesterol to apolipoprotein A-I with experimental results from the Women's Health Study</article-title>. <source>Clin Chem</source> <volume>59</volume>: <fpage>949</fpage>–<lpage>958</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003509-Scanu1"><label>26</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Scanu</surname><given-names>AM</given-names></name>, <name name-style="western"><surname>Edelstein</surname><given-names>C</given-names></name> (<year>2008</year>) <article-title>HDL: bridging past and present with a look at the future</article-title>. <source>FASEB J</source> <volume>22</volume>: <fpage>4044</fpage>–<lpage>4054</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003509-Kontush1"><label>27</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kontush</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Chapman</surname><given-names>MJ</given-names></name> (<year>2006</year>) <article-title>Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inammation, and atherosclerosis</article-title>. <source>Pharmacol Rev</source> <volume>58</volume>: <fpage>342</fpage>–<lpage>374</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003509-Moestrup1"><label>28</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Moestrup</surname><given-names>SK</given-names></name>, <name name-style="western"><surname>Kozyraki</surname><given-names>R</given-names></name> (<year>2000</year>) <article-title>Cubilin, a high-density lipoprotein receptor</article-title>. <source>Curr Opin Lipidol</source> <volume>11</volume>: <fpage>133</fpage>–<lpage>140</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003509-Martinez1"><label>29</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Martinez</surname><given-names>LO</given-names></name>, <name name-style="western"><surname>Jacquet</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Esteve</surname><given-names>JP</given-names></name>, <name name-style="western"><surname>Rolland</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Cabezon</surname><given-names>E</given-names></name>, <etal>et al</etal>. (<year>2003</year>) <article-title>Ectopic beta-chain of ATP synthase is an apolipoprotein A-I receptor in hepatic HDL endocytosis</article-title>. <source>Nature</source> <volume>421</volume>: <fpage>75</fpage>–<lpage>79</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003509-Chapman1"><label>30</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Chapman</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>Le Goff</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Guerin</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Kontush</surname><given-names>A</given-names></name> (<year>2010</year>) <article-title>Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors</article-title>. <source>Eur Heart J</source> <volume>31</volume>: <fpage>149</fpage>–<lpage>164</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003509-Aster1"><label>31</label>
<mixed-citation publication-type="book" xlink:type="simple">Aster R, Borchers B, Thurber C (2005) Parameter Estimation and Inverse Problems. Academic Press.</mixed-citation>
</ref>
<ref id="pcbi.1003509-Klinke1"><label>32</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Klinke</surname><given-names>DJ</given-names></name> (<year>2009</year>) <article-title>An empirical Bayesian approach for model-based inference of cellular signaling networks</article-title>. <source>BMC Bioinformatics</source> <volume>10</volume>: <fpage>371</fpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003509-Eydgahi1"><label>33</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Eydgahi</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>WW</given-names></name>, <name name-style="western"><surname>Muhlich</surname><given-names>JL</given-names></name>, <name name-style="western"><surname>Vitkup</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Tsitsiklis</surname><given-names>JN</given-names></name>, <etal>et al</etal>. (<year>2013</year>) <article-title>Properties of cell death models calibrated and compared using Bayesian approaches</article-title>. <source>Mol Syst Biol</source> <volume>9</volume>: <fpage>644</fpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003509-Gisleskog1"><label>34</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Gisleskog</surname><given-names>PO</given-names></name>, <name name-style="western"><surname>Karlsson</surname><given-names>MO</given-names></name>, <name name-style="western"><surname>Beal</surname><given-names>SL</given-names></name> (<year>2002</year>) <article-title>Use of prior information to stabilize a population data analysis</article-title>. <source>J Pharmacokinet Pharmacodyn</source> <volume>29</volume>: <fpage>473</fpage>–<lpage>505</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003509-Jonsson1"><label>35</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Jonsson</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Jonsson</surname><given-names>EN</given-names></name>, <name name-style="western"><surname>Bois</surname><given-names>FY</given-names></name>, <name name-style="western"><surname>Marshall</surname><given-names>S</given-names></name> (<year>2007</year>) <article-title>The application of a Bayesian approach to the analysis of a complex, mechanistically based model</article-title>. <source>J Biopharm Stat</source> <volume>17</volume>: <fpage>65</fpage>–<lpage>92</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003509-Vergeer1"><label>36</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Vergeer</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Korporaal</surname><given-names>SJ</given-names></name>, <name name-style="western"><surname>Franssen</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Meurs</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Out</surname><given-names>R</given-names></name>, <etal>et al</etal>. (<year>2011</year>) <article-title>Genetic variant of the scavenger receptor BI in humans</article-title>. <source>N Engl J Med</source> <volume>364</volume>: <fpage>136</fpage>–<lpage>145</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003509-Vaziri1"><label>37</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Vaziri</surname><given-names>ND</given-names></name>, <name name-style="western"><surname>Navab</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Fogelman</surname><given-names>AM</given-names></name> (<year>2010</year>) <article-title>HDL metabolism and activity in chronic kidney disease</article-title>. <source>Nat Rev Nephrol</source> <volume>6</volume>: <fpage>287</fpage>–<lpage>296</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003509-Fabre1"><label>38</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Fabre</surname><given-names>AC</given-names></name>, <name name-style="western"><surname>Vantourout</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Champagne</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Terce</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Rolland</surname><given-names>C</given-names></name>, <etal>et al</etal>. (<year>2006</year>) <article-title>Cell surface adenylate kinase activity regulates the F(1)-ATPase/P2Y (13)-mediated HDL endocytosis pathway on human hepatocytes</article-title>. <source>Cell Mol Life Sci</source> <volume>63</volume>: <fpage>2829</fpage>–<lpage>2837</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003509-Ritsch1"><label>39</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ritsch</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Drexel</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Amann</surname><given-names>FW</given-names></name>, <name name-style="western"><surname>Pfeifhofer</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Patsch</surname><given-names>JR</given-names></name> (<year>1997</year>) <article-title>Deficiency of cholesteryl ester transfer protein. Description of the molecular defect and the dissociation of cholesteryl ester and triglyceride transport in plasma</article-title>. <source>Arterioscler Thromb Vasc Biol</source> <volume>17</volume>: <fpage>3433</fpage>–<lpage>3441</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003509-Ikewaki1"><label>40</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ikewaki</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Nishiwaki</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Sakamoto</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Ishikawa</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Fairwell</surname><given-names>T</given-names></name>, <etal>et al</etal>. (<year>1995</year>) <article-title>Increased catabolic rate of low density lipoproteins in humans with cholesteryl ester transfer protein deficiency</article-title>. <source>J Clin Invest</source> <volume>96</volume>: <fpage>1573</fpage>–<lpage>1581</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003509-Teh1"><label>41</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Teh</surname><given-names>EM</given-names></name>, <name name-style="western"><surname>Dolphin</surname><given-names>PJ</given-names></name>, <name name-style="western"><surname>Breckenridge</surname><given-names>WC</given-names></name>, <name name-style="western"><surname>Tan</surname><given-names>MH</given-names></name> (<year>1998</year>) <article-title>Human plasma CETP deficiency: identification of a novel mutation in exon 9 of the CETP gene in a Caucasian subject from North America</article-title>. <source>J Lipid Res</source> <volume>39</volume>: <fpage>442</fpage>–<lpage>456</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003509-Carlson1"><label>42</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Carlson</surname><given-names>LA</given-names></name>, <name name-style="western"><surname>Holmquist</surname><given-names>L</given-names></name> (<year>1985</year>) <article-title>Evidence for the presence in human plasma of lecithin: cholesterol acyltransferase activity (beta-LCAT) specifically esterifying free cholesterol of combined pre-betaand beta-lipoproteins. Studies of fish eye disease patients and control subjects</article-title>. <source>Acta Med Scand</source> <volume>218</volume>: <fpage>197</fpage>–<lpage>205</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003509-Brinton1"><label>43</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Brinton</surname><given-names>EA</given-names></name>, <name name-style="western"><surname>Eisenberg</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Breslow</surname><given-names>JL</given-names></name> (<year>1994</year>) <article-title>Human HDL cholesterol levels are determined by apoA-I fractional catabolic rate, which correlates inversely with estimates of HDL particle size. Effects of gender, hepatic and lipoprotein lipases, triglyceride and insulin levels, and body fat distribution</article-title>. <source>Arterioscler Thromb</source> <volume>14</volume>: <fpage>707</fpage>–<lpage>720</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003509-Schaefer1"><label>44</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Schaefer</surname><given-names>EJ</given-names></name>, <name name-style="western"><surname>Zech</surname><given-names>LA</given-names></name>, <name name-style="western"><surname>Jenkins</surname><given-names>LL</given-names></name>, <name name-style="western"><surname>Bronzert</surname><given-names>TJ</given-names></name>, <name name-style="western"><surname>Rubalcaba</surname><given-names>EA</given-names></name>, <etal>et al</etal>. (<year>1982</year>) <article-title>Human apolipoprotein A-I and A-II metabolism</article-title>. <source>J Lipid Res</source> <volume>23</volume>: <fpage>850</fpage>–<lpage>862</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003509-Ikewaki2"><label>45</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ikewaki</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Rader</surname><given-names>DJ</given-names></name>, <name name-style="western"><surname>Sakamoto</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Nishiwaki</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Wakimoto</surname><given-names>N</given-names></name>, <etal>et al</etal>. (<year>1993</year>) <article-title>Delayed catabolism of high density lipoprotein apolipoproteins A-I and A-II in human cholesteryl ester transfer protein deficiency</article-title>. <source>J Clin Invest</source> <volume>92</volume>: <fpage>1650</fpage>–<lpage>1658</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003509-Asztalos1"><label>46</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Asztalos</surname><given-names>BF</given-names></name>, <name name-style="western"><surname>Brousseau</surname><given-names>ME</given-names></name>, <name name-style="western"><surname>McNamara</surname><given-names>JR</given-names></name>, <name name-style="western"><surname>Horvath</surname><given-names>KV</given-names></name>, <name name-style="western"><surname>Roheim</surname><given-names>PS</given-names></name>, <etal>et al</etal>. (<year>2001</year>) <article-title>Subpopulations of high density lipoproteins in homozygous and heterozygous Tangier disease</article-title>. <source>Atherosclerosis</source> <volume>156</volume>: <fpage>217</fpage>–<lpage>225</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003509-Santos1"><label>47</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Santos</surname><given-names>RD</given-names></name>, <name name-style="western"><surname>Schaefer</surname><given-names>EJ</given-names></name>, <name name-style="western"><surname>Asztalos</surname><given-names>BF</given-names></name>, <name name-style="western"><surname>Polisecki</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>J</given-names></name>, <etal>et al</etal>. (<year>2008</year>) <article-title>Characterization of high density lipoprotein particles in familial apolipoprotein A-I deficiency</article-title>. <source>J Lipid Res</source> <volume>49</volume>: <fpage>349</fpage>–<lpage>357</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003509-Ikewaki3"><label>48</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ikewaki</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Rader</surname><given-names>DJ</given-names></name>, <name name-style="western"><surname>Schaefer</surname><given-names>JR</given-names></name>, <name name-style="western"><surname>Fairwell</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Zech</surname><given-names>LA</given-names></name>, <etal>et al</etal>. (<year>1993</year>) <article-title>Evaluation of apoA-I kinetics in humans using simultaneous endogenous stable isotope and exogenous radiotracer methods</article-title>. <source>J Lipid Res</source> <volume>34</volume>: <fpage>2207</fpage>–<lpage>2215</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003509-Moss1"><label>49</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Moss</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Grosse</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Marchant</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Lassau</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Guey_er</surname><given-names>F</given-names></name>, <etal>et al</etal>. (<year>2012</year>) <article-title>Virtual patients and sensitivity analysis of the Guyton model of blood pressure regulation: towards individualized models of wholebody physiology</article-title>. <source>PLoS Comput Biol</source> <volume>8</volume>: <fpage>e1002571</fpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003509-Schwartz3"><label>50</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Schwartz</surname><given-names>GG</given-names></name>, <name name-style="western"><surname>Olsson</surname><given-names>AG</given-names></name>, <name name-style="western"><surname>Barter</surname><given-names>PJ</given-names></name> (<year>2013</year>) <article-title>Dalcetrapib in patients with an acute coronary syndrome</article-title>. <source>N Engl J Med</source> <volume>368</volume>: <fpage>869</fpage>–<lpage>870</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003509-Clark1"><label>51</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Clark</surname><given-names>RW</given-names></name>, <name name-style="western"><surname>Sutfin</surname><given-names>TA</given-names></name>, <name name-style="western"><surname>Ruggeri</surname><given-names>RB</given-names></name>, <name name-style="western"><surname>Willauer</surname><given-names>AT</given-names></name>, <name name-style="western"><surname>Sugarman</surname><given-names>ED</given-names></name>, <etal>et al</etal>. (<year>2004</year>) <article-title>Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib</article-title>. <source>Arterioscler Thromb Vasc Biol</source> <volume>24</volume>: <fpage>490</fpage>–<lpage>497</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003509-Cannon1"><label>52</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Cannon</surname><given-names>CP</given-names></name>, <name name-style="western"><surname>Shah</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Dansky</surname><given-names>HM</given-names></name>, <name name-style="western"><surname>Davidson</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Brinton</surname><given-names>EA</given-names></name>, <etal>et al</etal>. (<year>2010</year>) <article-title>Safety of anacetrapib in patients with or at high risk for coronary heart disease</article-title>. <source>N Engl J Med</source> <volume>363</volume>: <fpage>2406</fpage>–<lpage>2415</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003509-Voight1"><label>53</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Voight</surname><given-names>BF</given-names></name>, <name name-style="western"><surname>Peloso</surname><given-names>GM</given-names></name>, <name name-style="western"><surname>Orho-Melander</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Frikke-Schmidt</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Barbalic</surname><given-names>M</given-names></name>, <etal>et al</etal>. (<year>2012</year>) <article-title>Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study</article-title>. <source>Lancet</source> <volume>380</volume>: <fpage>572</fpage>–<lpage>580</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003509-Mackey1"><label>54</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Mackey</surname><given-names>RH</given-names></name>, <name name-style="western"><surname>Greenland</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Goff</surname><given-names>DC</given-names></name>, <name name-style="western"><surname>Lloyd-Jones</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Sibley</surname><given-names>CT</given-names></name>, <etal>et al</etal>. (<year>2012</year>) <article-title>High-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: MESA (multi-ethnic study of atherosclerosis)</article-title>. <source>J Am Coll Cardiol</source> <volume>60</volume>: <fpage>508</fpage>–<lpage>516</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003509-Sethi1"><label>55</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sethi</surname><given-names>AA</given-names></name>, <name name-style="western"><surname>Sampson</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Warnick</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Muniz</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Vaisman</surname><given-names>B</given-names></name>, <etal>et al</etal>. (<year>2010</year>) <article-title>High pre-beta1 HDL concentrations and low lecithin: cholesterol acyltransferase activities are strong positive risk markers for ischemic heart disease and independent of HDL-cholesterol</article-title>. <source>Clin Chem</source> <volume>56</volume>: <fpage>1128</fpage>–<lpage>1137</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003509-Kane1"><label>56</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kane</surname><given-names>JP</given-names></name>, <name name-style="western"><surname>Malloy</surname><given-names>MJ</given-names></name> (<year>2012</year>) <article-title>Prebeta-1 HDL and coronary heart disease</article-title>. <source>Curr Opin Lipidol</source> <volume>23</volume>: <fpage>367</fpage>–<lpage>371</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003509-Kaess1"><label>57</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kaess</surname><given-names>BM</given-names></name>, <name name-style="western"><surname>Tomaszewski</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Braund</surname><given-names>PS</given-names></name>, <name name-style="western"><surname>Stark</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Rafelt</surname><given-names>S</given-names></name>, <etal>et al</etal>. (<year>2011</year>) <article-title>Large-scale candidate gene analysis of HDL particle features</article-title>. <source>PLoS ONE</source> <volume>6</volume>: <fpage>e14529</fpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003509-Rothblat2"><label>58</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Rothblat</surname><given-names>GH</given-names></name>, <name name-style="western"><surname>de la Llera-Moya</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Atger</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Kellner-Weibel</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Williams</surname><given-names>DL</given-names></name>, <etal>et al</etal>. (<year>1999</year>) <article-title>Cell cholesterol efflux: integration of old and new observations provides new insights</article-title>. <source>J Lipid Res</source> <volume>40</volume>: <fpage>781</fpage>–<lpage>796</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003509-Patel1"><label>59</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Patel</surname><given-names>DC</given-names></name>, <name name-style="western"><surname>Albrecht</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Pavitt</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Paul</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Pourreyron</surname><given-names>C</given-names></name>, <etal>et al</etal>. (<year>2011</year>) <article-title>Type 2 diabetes is associated with reduced ATP-binding cassette transporter A1 gene expression, protein and function</article-title>. <source>PLoS ONE</source> <volume>6</volume>: <fpage>e22142</fpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003509-Paul1"><label>60</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Paul</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Meyer</surname><given-names>HH</given-names></name>, <name name-style="western"><surname>Leidl</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Soumian</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Albrecht</surname><given-names>C</given-names></name> (<year>2008</year>) <article-title>A novel enzyme immunoassay specific for ABCA1 protein quantification in human tissues and cells</article-title>. <source>J Lipid Res</source> <volume>49</volume>: <fpage>2259</fpage>–<lpage>2267</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003509-Nanjee1"><label>61</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Nanjee</surname><given-names>MN</given-names></name>, <name name-style="western"><surname>Brinton</surname><given-names>EA</given-names></name> (<year>2000</year>) <article-title>Very small apolipoprotein A-I-containing particles from human plasma: isolation and quantification by high-performance size-exclusion chromatography</article-title>. <source>Clin Chem</source> <volume>46</volume>: <fpage>207</fpage>–<lpage>223</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003509-Asztalos2"><label>62</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Asztalos</surname><given-names>BF</given-names></name>, <name name-style="western"><surname>Collins</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Cupples</surname><given-names>LA</given-names></name>, <name name-style="western"><surname>Demissie</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Horvath</surname><given-names>KV</given-names></name>, <etal>et al</etal>. (<year>2005</year>) <article-title>Value of high-density lipoprotein (HDL) subpopulations in predicting recurrent cardiovascular events in the Veterans Affairs HDL Intervention Trial</article-title>. <source>Arterioscler Thromb Vasc Biol</source> <volume>25</volume>: <fpage>2185</fpage>–<lpage>2191</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003509-Asztalos3"><label>63</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Asztalos</surname><given-names>BF</given-names></name>, <name name-style="western"><surname>Batista</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Horvath</surname><given-names>KV</given-names></name>, <name name-style="western"><surname>Cox</surname><given-names>CE</given-names></name>, <name name-style="western"><surname>Dallal</surname><given-names>GE</given-names></name>, <etal>et al</etal>. (<year>2003</year>) <article-title>Change in alpha1 HDL concentration predicts progression in coronary artery stenosis</article-title>. <source>Arterioscler Thromb Vasc Biol</source> <volume>23</volume>: <fpage>847</fpage>–<lpage>852</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003509-Hirayama1"><label>64</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hirayama</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Miida</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Miyazaki</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Aizawa</surname><given-names>Y</given-names></name> (<year>2007</year>) <article-title>Pre beta1-HDL concentration is a predictor of carotid atherosclerosis in type 2 diabetic patients</article-title>. <source>Diabetes Care</source> <volume>30</volume>: <fpage>1289</fpage>–<lpage>1291</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003509-deVries1"><label>65</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>de Vries</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Perton</surname><given-names>FG</given-names></name>, <name name-style="western"><surname>van Tol</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Dullaart</surname><given-names>RP</given-names></name> (<year>2012</year>) <article-title>Carotid intima media thickness is related positively to plasma pre -high density lipoproteins in non-diabetic subjects</article-title>. <source>Clin Chim Acta</source> <volume>413</volume>: <fpage>473</fpage>–<lpage>477</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003509-Guey1"><label>66</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Guey</surname><given-names>LT</given-names></name>, <name name-style="western"><surname>Pullinger</surname><given-names>CR</given-names></name>, <name name-style="western"><surname>Ishida</surname><given-names>BY</given-names></name>, <name name-style="western"><surname>O'Connor</surname><given-names>PM</given-names></name>, <name name-style="western"><surname>Zellner</surname><given-names>C</given-names></name>, <etal>et al</etal>. (<year>2011</year>) <article-title>Relation of increased prebeta-1 high-density lipoprotein levels to risk of coronary heart disease</article-title>. <source>Am J Cardiol</source> <volume>108</volume>: <fpage>360</fpage>–<lpage>366</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003509-Shah1"><label>67</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Shah</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Rader</surname><given-names>DJ</given-names></name>, <name name-style="western"><surname>Millar</surname><given-names>JS</given-names></name> (<year>2010</year>) <article-title>The effect of PPAR-alpha agonism on apolipoprotein metabolism in humans</article-title>. <source>Atherosclerosis</source> <volume>210</volume>: <fpage>35</fpage>–<lpage>40</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003509-Apostoli1"><label>68</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Apostoli</surname><given-names>AJ</given-names></name>, <name name-style="western"><surname>Nicol</surname><given-names>CJ</given-names></name> (<year>2012</year>) <article-title>PPAR Medicines and Human Disease: The ABCs of It All</article-title>. <source>PPAR Res</source> <volume>2012</volume>: <fpage>504918</fpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003509-Rodrigueza1"><label>69</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Rodrigueza</surname><given-names>WV</given-names></name>, <name name-style="western"><surname>Williams</surname><given-names>KJ</given-names></name>, <name name-style="western"><surname>Rothblat</surname><given-names>GH</given-names></name>, <name name-style="western"><surname>Phillips</surname><given-names>MC</given-names></name> (<year>1997</year>) <article-title>Remodeling and shuttling. Mechanisms for the synergistic effects between different acceptor particles in the mobilization of cellular cholesterol</article-title>. <source>Arterioscler Thromb Vasc Biol</source> <volume>17</volume>: <fpage>383</fpage>–<lpage>393</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003509-Tchoua1"><label>70</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Tchoua</surname><given-names>U</given-names></name>, <name name-style="western"><surname>Gillard</surname><given-names>BK</given-names></name>, <name name-style="western"><surname>Pownall</surname><given-names>HJ</given-names></name> (<year>2010</year>) <article-title>HDL superphospholipidation enhances key steps in reverse cholesterol transport</article-title>. <source>Atherosclerosis</source> <volume>209</volume>: <fpage>430</fpage>–<lpage>435</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003509-Shen1"><label>71</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Shen</surname><given-names>BW</given-names></name>, <name name-style="western"><surname>Scanu</surname><given-names>AM</given-names></name>, <name name-style="western"><surname>Kezdy</surname><given-names>FJ</given-names></name> (<year>1977</year>) <article-title>Structure of human serum lipoproteins inferred from compositional analysis</article-title>. <source>Proc Natl Acad Sci USA</source> <volume>74</volume>: <fpage>837</fpage>–<lpage>841</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003509-Li1"><label>72</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Li</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Stolinski</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Umpleby</surname><given-names>AM</given-names></name> (<year>2012</year>) <article-title>Development of a method to measure pre–<italic>β</italic> HDL and <italic>α</italic>–HDL apoA-I enrichment for stable isotopic studies of HDL kinetics</article-title>. <source>Lipids</source> <volume>47</volume>: <fpage>1011</fpage>–<lpage>1018</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003509-Braschi1"><label>73</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Braschi</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Neville</surname><given-names>TA</given-names></name>, <name name-style="western"><surname>Maugeais</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Ramsamy</surname><given-names>TA</given-names></name>, <name name-style="western"><surname>Seymour</surname><given-names>R</given-names></name>, <etal>et al</etal>. (<year>2000</year>) <article-title>Role of the kidney in regulating the metabolism of HDL in rabbits: evidence that iodination alters the catabolism of apolipoprotein A-I by the kidney</article-title>. <source>Biochemistry</source> <volume>39</volume>: <fpage>5441</fpage>–<lpage>5449</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003509-Bojanovski1"><label>74</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Bojanovski</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Gregg</surname><given-names>RE</given-names></name>, <name name-style="western"><surname>Zech</surname><given-names>LA</given-names></name>, <name name-style="western"><surname>Meng</surname><given-names>MS</given-names></name>, <name name-style="western"><surname>Bishop</surname><given-names>C</given-names></name>, <etal>et al</etal>. (<year>1987</year>) <article-title>In vivo metabolism of proapolipoprotein A-I in Tangier disease</article-title>. <source>J Clin Invest</source> <volume>80</volume>: <fpage>1742</fpage>–<lpage>1747</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003509-Schaefer2"><label>75</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Schaefer</surname><given-names>EJ</given-names></name>, <name name-style="western"><surname>Anderson</surname><given-names>DW</given-names></name>, <name name-style="western"><surname>Zech</surname><given-names>LA</given-names></name>, <name name-style="western"><surname>Lindgren</surname><given-names>FT</given-names></name>, <name name-style="western"><surname>Bronzert</surname><given-names>TB</given-names></name>, <etal>et al</etal>. (<year>1981</year>) <article-title>Metabolism of high density lipoprotein subfractions and constituents in Tangier disease following the infusion of high density lipoproteins</article-title>. <source>J Lipid Res</source> <volume>22</volume>: <fpage>217</fpage>–<lpage>228</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003509-Cavigiolio1"><label>76</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Cavigiolio</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Geier</surname><given-names>EG</given-names></name>, <name name-style="western"><surname>Shao</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Heinecke</surname><given-names>JW</given-names></name>, <name name-style="western"><surname>Oda</surname><given-names>MN</given-names></name> (<year>2010</year>) <article-title>Exchange of apolipoprotein A-I between lipid-associated and lipid-free states: a potential target for oxidative generation of dysfunctional high density lipoproteins</article-title>. <source>J Biol Chem</source> <volume>285</volume>: <fpage>18847</fpage>–<lpage>18857</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003509-Cheung1"><label>77</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Cheung</surname><given-names>MC</given-names></name>, <name name-style="western"><surname>Wolf</surname><given-names>AC</given-names></name>, <name name-style="western"><surname>Knopp</surname><given-names>RH</given-names></name>, <name name-style="western"><surname>Foster</surname><given-names>DM</given-names></name> (<year>1992</year>) <article-title>Protein transfer between A-I-containing lipoprotein subpopulations: evidence of non-transferable A-I in particles with A-II</article-title>. <source>Biochim Biophys Acta</source> <volume>1165</volume>: <fpage>68</fpage>–<lpage>77</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003509-LundKatz1"><label>78</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lund-Katz</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Nguyen</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Dhanasekaran</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Kono</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Nickel</surname><given-names>M</given-names></name>, <etal>et al</etal>. (<year>2010</year>) <article-title>Surface plasmon resonance analysis of the mechanism of binding of apoA-I to high density lipoprotein particles</article-title>. <source>J Lipid Res</source> <volume>51</volume>: <fpage>606</fpage>–<lpage>617</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003509-Castro1"><label>79</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Castro</surname><given-names>GR</given-names></name>, <name name-style="western"><surname>Fielding</surname><given-names>CJ</given-names></name> (<year>1988</year>) <article-title>Early incorporation of cell-derived cholesterol into pre-betamigrating high-density lipoprotein</article-title>. <source>Biochemistry</source> <volume>27</volume>: <fpage>25</fpage>–<lpage>29</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003509-SorciThomas1"><label>80</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sorci-Thomas</surname><given-names>MG</given-names></name>, <name name-style="western"><surname>Owen</surname><given-names>JS</given-names></name>, <name name-style="western"><surname>Fulp</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Bhat</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Zhu</surname><given-names>X</given-names></name>, <etal>et al</etal>. (<year>2012</year>) <article-title>Nascent high density lipoproteins formed by ABCA1 resemble lipid rafts and are structurally organized by three apoA-I monomers</article-title>. <source>J Lipid Res</source> <volume>53</volume>: <fpage>1890</fpage>–<lpage>1909</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003509-Inazu1"><label>81</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Inazu</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Brown</surname><given-names>ML</given-names></name>, <name name-style="western"><surname>Hesler</surname><given-names>CB</given-names></name>, <name name-style="western"><surname>Agellon</surname><given-names>LB</given-names></name>, <name name-style="western"><surname>Koizumi</surname><given-names>J</given-names></name>, <etal>et al</etal>. (<year>1990</year>) <article-title>Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation</article-title>. <source>N Engl J Med</source> <volume>323</volume>: <fpage>1234</fpage>–<lpage>1238</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003509-Yamashita1"><label>82</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Yamashita</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Hui</surname><given-names>DY</given-names></name>, <name name-style="western"><surname>Wetterau</surname><given-names>JR</given-names></name>, <name name-style="western"><surname>Sprecher</surname><given-names>DL</given-names></name>, <name name-style="western"><surname>Harmony</surname><given-names>JA</given-names></name>, <etal>et al</etal>. (<year>1991</year>) <article-title>Characterization of plasma lipoproteins in patients heterozygous for human plasma cholesteryl ester transfer protein (CETP) deficiency: plasma CETP regulates high-density lipoprotein concentration and composition</article-title>. <source>Metab Clin Exp</source> <volume>40</volume>: <fpage>756</fpage>–<lpage>763</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003509-Asztalos4"><label>83</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Asztalos</surname><given-names>BF</given-names></name>, <name name-style="western"><surname>Horvath</surname><given-names>KV</given-names></name>, <name name-style="western"><surname>Kajinami</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Nartsupha</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Cox</surname><given-names>CE</given-names></name>, <etal>et al</etal>. (<year>2004</year>) <article-title>Apolipoprotein composition of HDL in cholesteryl ester transfer protein deficiency</article-title>. <source>J Lipid Res</source> <volume>45</volume>: <fpage>448</fpage>–<lpage>455</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003509-Press1"><label>84</label>
<mixed-citation publication-type="book" xlink:type="simple">Press WH, Teukolsky SA, Vetterling WT, Flannery BP (1992) Numerical recipes in C (2nd ed.): the art of scientific computing. Cambridge, UK: Cambridge University Press.</mixed-citation>
</ref>
<ref id="pcbi.1003509-Martins1"><label>85</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Martins</surname><given-names>JRRA</given-names></name>, <name name-style="western"><surname>Sturdza</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Alonso</surname><given-names>JJ</given-names></name> (<year>2003</year>) <article-title>The complex-step derivative approximation</article-title>. <source>ACM Trans Math Software</source> <volume>29</volume>: <fpage>245</fpage>–<lpage>262</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003509-Apgar1"><label>86</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Apgar</surname><given-names>JF</given-names></name>, <name name-style="western"><surname>Witmer</surname><given-names>DK</given-names></name>, <name name-style="western"><surname>White</surname><given-names>FM</given-names></name>, <name name-style="western"><surname>Tidor</surname><given-names>B</given-names></name> (<year>2010</year>) <article-title>Sloppy models, parameter uncertainty, and the role of experimental design</article-title>. <source>Mol Biosyst</source> <volume>6</volume>: <fpage>1890</fpage>–<lpage>1900</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003509-Wei1"><label>87</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Wei</surname><given-names>XN</given-names></name>, <name name-style="western"><surname>Han</surname><given-names>BC</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>JX</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>XH</given-names></name>, <name name-style="western"><surname>Tan</surname><given-names>CY</given-names></name>, <etal>et al</etal>. (<year>2011</year>) <article-title>An integrated mathematical model of thrombin-, histamine-and VEGF-mediated signalling in endothelial permeability</article-title>. <source>BMC Syst Biol</source> <volume>5</volume>: <fpage>112</fpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003509-VelezCarrasco1"><label>88</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Velez-Carrasco</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Lichtenstein</surname><given-names>AH</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Dolnikowski</surname><given-names>GG</given-names></name>, <name name-style="western"><surname>Lamon-Fava</surname><given-names>S</given-names></name>, <etal>et al</etal>. (<year>2000</year>) <article-title>Apolipoprotein A-I and A-II kinetic parameters as assessed by endogenous labeling with [(2)H(3)]leucine in middle-aged and elderly men and women</article-title>. <source>Arterioscler Thromb Vasc Biol</source> <volume>20</volume>: <fpage>801</fpage>–<lpage>806</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003509-Schaefer3"><label>89</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Schaefer</surname><given-names>EJ</given-names></name>, <name name-style="western"><surname>Santos</surname><given-names>RD</given-names></name>, <name name-style="western"><surname>Asztalos</surname><given-names>BF</given-names></name> (<year>2010</year>) <article-title>Marked HDL deficiency and premature coronary heart disease</article-title>. <source>Curr Opin Lipidol</source> <volume>21</volume>: <fpage>289</fpage>–<lpage>297</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003509-Barter2"><label>90</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Barter</surname><given-names>PJ</given-names></name> (<year>2002</year>) <article-title>Hugh Sinclair Lecture: the regulation and remodelling of HDL by plasma factors</article-title>. <source>Atheroscler</source> <volume>Suppl 3</volume>: <fpage>39</fpage>–<lpage>47</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003509-Miyazaki1"><label>91</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Miyazaki</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Fukamachi</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Mori</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Hashimoto</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Kawashiri</surname><given-names>MA</given-names></name>, <etal>et al</etal>. (<year>2009</year>) <article-title>Formation of prebeta1-HDL during lipolysis of triglyceride-rich lipoprotein</article-title>. <source>Biochem Biophys Res Commun</source> <volume>379</volume>: <fpage>55</fpage>–<lpage>59</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003509-Liang1"><label>92</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Liang</surname><given-names>HQ</given-names></name>, <name name-style="western"><surname>Rye</surname><given-names>KA</given-names></name>, <name name-style="western"><surname>Barter</surname><given-names>PJ</given-names></name> (<year>1994</year>) <article-title>Dissociation of lipid-free apolipoprotein A-I from high density lipoproteins</article-title>. <source>J Lipid Res</source> <volume>35</volume>: <fpage>1187</fpage>–<lpage>1199</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003509-Settasatian1"><label>93</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Settasatian</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Duong</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Curtiss</surname><given-names>LK</given-names></name>, <name name-style="western"><surname>Ehnholm</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Jauhiainen</surname><given-names>M</given-names></name>, <etal>et al</etal>. (<year>2001</year>) <article-title>The mechanism of the remodeling of high density lipoproteins by phospholipid transfer protein</article-title>. <source>J Biol Chem</source> <volume>276</volume>: <fpage>26898</fpage>–<lpage>26905</lpage>.</mixed-citation>
</ref>
</ref-list></back>
</article>